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5SUMMARY
The series of investigations presented in this thesis examined different 
methods of assessing chronic pain in dogs suffering from osteoarthritis 
(OA) and compared the effects of three different treatments. Data were 
obtained from two cohorts; 41 dogs with OA due to canine hip dysplasia 
(CHD) (I,III) and 61 dogs with OA due to CHD or elbow dysplasia 
(II,IV,V). 
Questionnaires, veterinary evaluations, visual analog scales (VAS), 
plasma hormones, radiographs, and force plate evaluations were assessed as 
OA treatment outcome measures and/or measurements of chronic pain.
The results indicated that the multidimensional pain scale including 11 
questions, each with five responses to choose from, was a valid and reliable 
tool for evaluating chronic pain. This Helsinki chronic pain index (HCPI) 
can be applied as an outcome measure in clinical trials where chronic pain 
is evaluated by owners. 
Of the evaluated complementary therapies for chronic pain due to OA, 
all three indicated a positive treatment outcome. In the first trial, gold 
bead implants resulted in a significant positive treatment outcome for the 
treatment group. However, the placebo group in this study also improved 
significantly. A positive effect was seen in 53 to 63% of the placebo dogs and 
this unnormally high incidence of amelioration suggests that the placebo 
group may have got an effect of unintentional needle acupuncture. The 
results of this study are therefore controversial and treatment guidelines 
based on these findings cannot be given.
The second trial tested two ingestible OA remedies, green lipped mussel 
and a homeopathic low-dose combination preparation. Both treatments 
resulted in statistically significant positive treatment outcomes compared 
with placebo, but with the positive control (carprofen) being more effective 
than either of them. The results suggest that both tested treatments may 
be beneficial for chronic OA. To establish the true role of all these three 
treatments in outcome-based animal analgesia, more clinical trials, using 
larger cohorts, should be conducted. Possible of action mechanisms should 
also be studied.
6“Man who says it can’t be done 
should not interrupt woman doing it”
-slightly modified Chinese proverb
This work is dedicated to the memory of my parents: 
To my father,
 who taught me to keep an open mind 
 but to question everything, 
and to
my mother,
 who taught me 
how to handle 1000 things simultaneously,
 and love it.
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AFOS = alkaline phosphatase
ALAT = alanine aminotransferase
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BMP = Bone morphogenetic proteins
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CAM = complementary and alternative medicine
CDMP = cartilage-derived morphogenetic protein
CHD = canine hip dysplasia
CI = confidence interval 
CIA = collagen induced arthritis
CONSORT = consolidated standards of reporting trials
COX = cyclooxygenase (e.g. COX-1) 
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DJD = degenerative joint disease
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DNIC = diffuse noxious inhibitory control
EA = electroacupuncture 
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GLM = green lipped mussel
GRF = ground reaction force
HCP = homeopathic combination preparation
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IGF-1 = insuline-like growth factor-1
IFN-γ = interferon γ
IL-1 = interleukin-1 (also IL-6, IL-17…)
IVAS = International Veterinary Acupuncture Society 
LIF = leukemia inhibitory factor
LOX = lipoxygenase (e.g. 5-LOX or simply 5-LO)
MDS = multifactorial descriptive scale
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MMP-1 = matrix metalloproteinase-1 (also MMP-3, -8…) 
NFκB = nuclear factor κB
NIH = National Institutes of Health (USA)
NK = natural killer (cell)
NMES = neuromuscular electric stimulation
NO = nitric oxide  
NSAID = nonsteroidal anti-inflammatory drug
OA = osteoarthritis
PC = principal component 
PCA = principal component analysis 
PDGF = platelet-derived growth factor
PDS = potential data-supported value
PG = prostaglandin (e.g. PGE2)
PSGAG = polysulphated glycosaminoglycan
PUFA = polyunsaturated fatty acid
PVF = peak vertical force
RCT = randomized controlled trial
ROM = range of motion
SD = standard deviation
SDS = simple descriptive scale
TENS = transcutaneous electrical nerve stimulation
TGF-β = transforming growth factor-β
TNF-α = tumour necrosis factor-α
VAS = visual analog scale
Wn= W for week and the subscript number for the week in question. 
        W0 is baseline.
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1. INTRODUCTION
Canine osteoarthritis (OA) is frequently encountered in small animal 
practice; canine hip dysplasia (CHD) and elbow dysplasia (ED) are two 
common forms (Innes 2005). As both conditions are usually lifelong and 
degenerate rather than improve, it is of the utmost importance to treat these 
dogs. OA is also the most common of human musculoskeletal diseases and 
it is rapidly becoming a significant medical and financial burden to the 
world (Pelletier et al. 2006). Moreover, a second financial burden comes 
from treating people suffering from side-effects that come as a consequence 
of OA pain therapy. As a consequence, recommendations have been made 
to use more natural disease-modifying agents in the pain management of 
human OA rather than nonsteroidal anti-inflammatory drugs (NSAIDs) 
(Pendleton et al. 2000). To this end, more research is being conducted to 
find less detrimental medication and treatments to replace the long-term 
administration of NSAIDs or the renewable injections of corticosteroids, 
which today still are the widest used treatment options, although they are 
not ideal due to the risk of adverse reactions. 
In evidence-based medicine (EBM), randomized controlled trials are 
crucial in the decision-making of which treatment to use, for doctors and 
veterinarians alike. Few of the new complementary OA treatments are 
registered drugs or treatments for animals, with many of them still lacking 
thorough testing and adequate clinical trials. There is, however, abundant 
research emerging in this field. In reviewing the Cochrane Library, 
which uses the EBM concept to do meta-analyses on recent randomized 
controlled trials (RCT) for different treatments of human OA, the following 
evaluations of new treatments for OA are presented: there is “convincing 
evidence for avocado-soybean unsaponifiables” (Little et al. 2003), 
“statistically significant improvement in all variables for electromagnetic 
field treatment for knee OA” (Hulme et al. 2003), “TENS (transcutaneous 
electrical nerve stimulation) and acupuncture-like-TENS are both shown 
to be effective in pain control over placebo” (Osiri et al. 2003), all 16 RCT 
trials showed that “glucosamine is both effective and safe” (Towheed et al. 
2003), whereas “results are conflicting in different studies” when assessing 
low-level laser therapy for treating OA (Brosseau et al. 2003a). A review on 
homeopathy for osteoarthritis is expected to be published in the Cochrane 
library 2008, Issue 1 (Munar et al. 2007).
Complementary medicine (also referred to as alternative medicine or 
CAM) is a highly sensitive topic among many doctors and researchers, in 
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both human and veterinary medicine. Complementary research studies 
have often had poor study designs and therefore low credibility. Most of 
this type of research has been done as summed case studies by clinicians 
without adequate research competence and training. For some years now, 
increasingly more, and better quality, research in complementary and 
alternative medicine has been conducted in universities, large research 
centers, and even at the government level by both the European Union 
and the US Food and Drug administration (FDA). Also, poor research 
design is not exclusive to complementary medicine; in the same issue of 
the Cochrane Library on OA treatments, regarding a meta-analysis on 
NSAIDs for treating OA of the knee, the reviewers concluded: “In spite 
of the large number of publications in this area, there are few randomized 
controlled trials. Furthermore, most trials comparing two or more NSAIDs 
suffer from substantial design errors” (Watson et al. 2003). 
As was seen from the Cochrane studies, many treatments are available 
for OA that could be evaluated also for dogs. Canine OA is a progressive 
and deliberating disease, very similar to the human disease, and the side-
effects from NSAIDs in dogs are also notable (MacPhail et al. 1998, FDA 
1999). Therefore, the need to evaluate new, less dangerous therapies for 
canine OA is the same as in the human disease. As canine OA is used as 
a model for human OA (Pond & Nuki 1973, Stoker et al. 2006) and as all 
of the treatments for the disease are available both for humans and dogs, 
the outcomes of these studies should also be of major interest for human 
medicine.
The alternative therapies most commonly used in veterinary medicine 
appear to be acupuncture, herbal medicine, and homeopathy (Hektoen 
2005), together with nutraceuticals, a newer group that also may contain 
animal-like products. Although still subject to debate, acupuncture is 
gaining acceptance in academic medicine because its mechanisms of 
action can to some extent be scientifically explained (see reviews in Steiss 
2001, Ma et al. 2005), and its clinical effects have been clinically evaluated 
and recommended for some conditions in human beings (ter Riet et al. 
1990, NIH 1998). Herbal medicine and nutraceuticals are not theoretically 
incompatible with existing medical science, but documentation of the 
clinical effects for specific conditions has thus far been limited. This is, 
however, changing, as can be seen from the large number of recently 
published studies and reviews (DeHaan et al. 1994, Innes et al. 2000, 
2003, Bauer 2001, Bierer & Bui 2002, Moreau et al. 2003, McCarthy et al. 
2007). In contrast, the potential effects of the highly diluted homeopathic 
remedies cannot be explained in terms of current scientific theories, and 
thus these remedies are highly controversial in both human and animal 
medicine (Hektoen 2005). The three treatments tested here fall into each of 
these categories and will be reviewed together with the more conventional 
treatments for canine OA.
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To be able to evaluate the clinical outcome of treatments for OA, 
measures evaluating pain or other OA symptoms are of the utmost 
importance. Pain is a subjective sensation and therefore should be assessed 
by the subject himself. For dogs, however, we must rely on veterinarians’ 
and owners’ views of the animal’s abnormal locomotion or behavior. At the 
time of our first clinical trial, no validated canine chronic pain assessment 
scores were available.
This thesis evaluated relatively unknown OA treatments for dogs in 
rigorous, randomized, controlled, or double-controlled, double-blind 
trials. We also developed and evaluated pain assessment methods for dogs 
with chronic pain. 
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REVIEW OF THE LITERATURE 2. 
 canine osteoarthritis (oa)2.1 
Osteoarthritis (OA) is the most common arthropathy affecting dogs 
(Bennett & May 1995). An estimated 20% of the canine population in the 
United Kingdom and in USA suffer from OA (Moore et al. 2001). It is 
a disorder of movable joints characterized by degeneration of articular 
cartilage and the formation of new bone at joint surfaces or margins 
(Bennett & May 1995). The term OA indicates degenerative joint disease 
(DJD) with concurrent synovial inflammation, which, however, is not 
invariably present (Altman & Gray 1985, Bennett & May 1995). DJD is a 
term preferred by many clinicians, as it indicates a pathological process not 
always associated with inflammation. However, OA appears to be the term 
that is most commonly used in the veterinary literature (Vaughan-Scott & 
Taylor 1997) and will therefore be used throughout the thesis. 
OA has been divided into two forms: primary and secondary OA. 
Primary OA is the result of defective articular cartilage structure and 
biosynthesis and is uncommon in dogs (Bennett & May 1995). Aspden 
et al. (2001) hypothesized that OA might in fact be a systemic disorder 
that affects the whole musculoskeletal system and involves altered lipid 
metabolism. Secondary OA results from abnormal forces acting on a 
normal joint (overweight, fracture, luxation, infection, crystal arthropathy, 
or immune mediated inflammation) or normal forces acting on an 
abnormal joint (abnormal joint conformation, osteochondrosis, hip and 
elbow dysplasia) (Bennett & May 1995, Innes 2005). Both in dogs and in 
humans, overweight has been shown to be a direct causative factor of OA, 
and losing weight significantly reduces the risk for OA (Felson et al. 1988, 
1992, Kealy et al. 1992, 1997, 2000, Smith et al. 2006). Losing weight has 
significantly improved hind limb lameness in dogs with CHD (Impellizeri 
et al. 2000). However, it is still unclear whether the cause of OA is purely 
a mechanical overload or of metabolic origin, as OA changes exist also 
in nonload-bearing joints, such as human hands (Oliveira et al. 1995). 
Human and canine patients with early OA have a proliferation of poorly 
mineralized bone and an increased bone mineral density (Li & Aspden 
1997, Chalmers et al. 2006). OA should be considered a disease process, 
the final common pathway for joint failure. Clinical manifestations of OA 
include pain and limited mobility in one or multiple joints. 
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cartilage structure2.1.1 
Normal cartilage consists of a small number of chondrocytes embedded in 
matrix (Fig. 1 b). The matrix, comprising water, collagen, and proteoglycans, 
is formed by chondrocytes (Fig 1c). The proteoglycan aggregates (Fig. 1 
d) are made of numerous proteoglycan monomers bound to hyaluronic 
acid. Each proteoglycan is made up of several mucopolysaccharides called 
glycosaminoglycans (GAGs) (about 95%) attached to a core protein (about 
5%), which in turn is joined to the hyaluronic acid molecule by a link 
protein. The GAGs in cartilage are chondroitin-4-sulphate, chondroitin-6-
sulphate, hyaluronic acid, keratan sulphate, dermatan sulphate, and heparin 
sulphate. Chondroitin sulphate is composed of repeating disaccharide 
units of glucosamine and galactosamine. Glucosamine is either formed 
from a nutritional supplement or synthesized from glucose and amino 
acids. Galactosamine is formed from glucosamine by changing one of the 
hydroxyl groups (Heinegård & Sommarin 1987). 
Fig 1. Components of normal cartilage 
As the proteoglycan forms complexes with the hyaluronic acid, it acts 
as an osmotic trap to hold the water between the collagen strands (May 
1994). Together, the water and the proteoglycan act as a shock absorber 
that enables cartilage to withstand normal loading forces (Clark 1991). As 
the cartilage is loaded, water is squeezed to the surface and the matrix is 
compressed. As the load is removed, water is reabsorbed by the cartilage 
and its shape is restored. Cartilage is not static but a living tissue and 
constantly regenerating; the chondrocytes are continually involved in 
normal anabolic repair processes of the matrix (Clark 1991). 
oA pathophysiology and biochemistry2.1.2 
The exact mechanisms of cartilage degeneration are not fully understood. 
OA can be studied on at least three different levels: (1) gross joint and 
cartilage changes, (2) the destructive cellular enzymes released during 
inflammation (matrix metalloproteinases [MMP]) and, (3) the cellular and 
molecular triggers (cytokines and nitric oxide [NO]) (Millis 2005)(Fig. 2). 
OA results from catabolic processes exceeding anabolic processes (Clark 
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1991). Articular cartilage undergoes softening and fibrillation early in OA. 
Cartilage fragments and matrix degradation products are released from the 
damaged cartilage. When degeneration exceeds regeneration, it will lead to 
synthesis of proteoglycans with an abnormal biochemical structure, loss of 
proteoglycans, and an abnormal cartilage structure (Clark 1991). Certain 
types of lymph node cells increase in collagen-induced arthritis (CIA), 
indicating that T cells and B cells are key participants in OA pathogenesis 
(Yim et al. 2007). Activated T cells promote disease progression by inducing 
secretion of proinflammatory cytokines from macrophages and synovial 
cells. In early OA, several of these destructive cytokines (IL-1, IL-6, 
IL-17, IL-18, TNF-α, LIF, and IFN-γ) trigger the release of enzymes that 
influence proteoglycan synthesis and are involved in cartilage degradation 
(May 1994, Miossec 2004, Yim et al. 2007). Cartilage degeneration leads 
to localized areas of soft cartilage, flaking, fissures, and decreased load-
bearing capacity (Bennett & May 1995). Other anabolic cytokines (growth 
factors IGF-1, TGF-β, FGF, PDGF, and CDMP) try to counteract cartilage 
degeneration (Goldring & Goldring 2004). The synovial fluid quality 
decreases in inflammation due to defective hyaluronic acid synthesis and 
increased catabolism. This leads to decreased lubrication and additional 
cartilage trauma. Hypoxia results in lactate accumulation in the synovia 
and a low pH. Proteoglycans and type II collagen can further act as antigens 
when released into the synovia. They provoke an inflammatory response, 
releasing proteinases, prostaglandins (PGs), cytokines (IL-1, TNF-α), and 
free radicals, such as NO, all of which directly or indirectly catabolize 
cartilage, bone, and hyaluronic acid (Goldring & Goldring 2004). IL-1 
triggers production of cyclooxygenase-2 (COX-2) in chondrocytes, inhibits 
synthesis of type II collagen, which is essential to articular cartilage, and 
stimulates type I and III collagen, contributing to fibrosis (Goldring & 
Goldring 2004). NO has a negative effect on chondrocytes as it activates 
catabolic enzymes, the metalloproteinases (MMP-1= collagenase, MMP-3= 
stromelysin, and MMP-8= gelatinase), decreases collagen and proteoglycan 
synthesis, and induces chondrocyte apoptosis (Goldring & Goldring 
2004). 1 and 2 aggrecanases (ADAM-TS 4 and -5) are similar to MMPs and 
the main enzymes responsible for the aggrecan catabolism in canine OA 
(Glasson et al 2005, Innes et al. 2005). In response to cellular necrosis and 
trauma, the subchondral bone and the zone of calcified cartilage, remodels 
and thickens (Daubs et al. 2006), altering their mechanical compliance. 
This again increases load-bearing stresses on the articular cartilage that 
decrease in thickness and lead to cartilage failure (Daubs et al. 2006). 
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Fig.2. Simplified schematic representation of the cytokine regulated pathogenesis of 
OA (a modified version of a slide from Millis 2005, with his permission, complied from 
research findings presented in the text (mainly from Sandell & Aigner 2001, Goldring 
& Goldring 2004). For abbrevations see list at p.13–14.
canine hip dysplasia (cHd)2.1.3 
Canine hip dysplasia (CHD) is a disease in dogs that causes laxity, abnormal 
development and, arthritis of the hip joint (Bennett & May 1995). The 
clinical consequences of CHD are extremely variable from dog to dog. 
CHD is an abnormal development or growth of the coxofemoral joint, 
usually bilateral (Brinker et al. 1990). It is manifested by varying degrees 
of laxity of surrounding soft tissues, instability, and malformation of the 
femoral head and acetabulum, eventually leading to OA (Smith & McKelvie 
1995). The hips are normal at birth, but failure of muscles and skeleton to 
mature together at the right time results in joint instability (Bennett & May 
1995). The prevailing hypotheses are that the incidence of CHD can be 
reduced by restricting food intake (Smith et al. 2006) and the growth rate 
of puppies. Excessive calcium, total energy, and/or protein consumption at 
an early age has an influence on the disease, with overweight (Smith et al. 
2006) and too heavy exercise (Black 1988, Cardinet et al. 1997), also playing 
a role. CHD has a polygenic mode of inheritance, and thus genetic selection 
will help to improve hip quality (Leighton 1997). In Finland, some breeds 
continue to have a high proportion of this disease: German Shepherd dogs 
44%, Golden Retrievers 39%, Berner Sennen dogs 52% (Official Statistics 
of the Finnish Kennel Club 1988-2007), even after 44 years of systematic 
radiographic selection of only mildly affected or CHD-free individuals for 
breeding. Also, as radiographs of individuals with severe OA changes often 
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are not submitted for official evaluation, the true incidence is probably 
much higher (Paster et al. 2005). A study from USA has shown that 
radiographs with normal appearing hips were 8.2 times more likely to be 
sent to the Orthopaedic Foundation for Animals (OFA) than radiographs 
of non-normal hips, and that 78% of Golden Retriever hip radiographs 
that were not submitted were abnormal (Paster et al. 2005). 
The earliest clinical sign of OA due to CHD is pain at full hind limb 
extension. Clinical signs of more advanced arthritis include loss of extension 
and abduction, muscle atrophy, and sometimes, an indistinct Ortolani sign 
(Montgomery 1998). The clinical presentation of CHD has been divided 
into two forms (Smith & McKelvie 1995): a severe form and a chronic form. 
The severe form typically appears between 5 and 12 months of age and shows 
signs of marked debilitating lameness, such as a noticeably abnormal gait, 
pain, low exercise tolerance, reluctance to go up and down stairs, atrophy of 
thigh muscles, occasionally an audible click when walking, and sometimes, 
if very severe, an obviously increased intertrochanteric (rump) width (Smith 
& McKelvie 1995). The chronic form, however, comprises the vast majority 
of cases. Dogs affected with this form can be totally asymptomatic, only 
mildly painful, or severely painful and disabled, particularly after periods of 
rest following excessive exercise or unaccustomed activity. This form often 
becomes evident with age and is characterized by a slow worsening of such 
signs as waddling gait, “bunny-hopping” when running, stiffness, slowness, 
reluctance to walk stairs, prefers to sit, slowness when rising, and excessive 
circling before lying down (Brinker et al. 1990). The Ortolani sign is rarely 
present owing to the shallowness of the acetabulum and fibrosis of the joint 
capsule (Brinker et al. 1990). Although less acute and debilitating than the 
severe form, the chronic form can progress to marked disuse and severe 
muscular wasting (Smith & McKelvie 1995). The clinical signs in chronic 
CHD are due to progression of OA (Smith & McKelvie 1995). Cold, damp, 
obesity and prolonged exercise often worsen signs of lameness (Bennett & 
May 1995). 
A tentative diagnosis can be made on the basis of history, clinical signs, 
and palpation. A definitive diagnosis is, however, made only when the hip 
joint shows characteristic radiographic signs of CHD. The radiographs are 
taken with the dog sedated, either in a supine position with the limbs fully 
extended and the stifles mildly internally rotated or with the limbs in a 
froglike position (e.g. using the PennHip method). In Finland, the limbs 
are fully extended and a 5 point evaluation is used (FCI 1991); A= no signs 
of CHD, B= close to normal hip joints, C= mild CHD, D= moderate CHD, 
and E= severe CHD.
elbow dysplasia (ed)2.1.4 
Elbow disease and elbow dysplasia (ED) are both umbrella terms for at least 
four different elbow pathologies; fragmentation of the medial coronoid 
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process, osteochondrosis dissecans of the medial humeral condyle, ununited 
anconeal process, and elbow incongruity. No scientific evidence indicates 
that these are true dysplasias, and it is probably unjustified to group such 
different entities with different etio-pathogeneses under the same name 
(Innes 2005). However, the term has been adopted internationally and will 
be used here as well. 
As with CHD, ED either includes OA changes or not. At the stage when 
radiographic changes are seen, OA is mostly already present (Bennett & 
May 1995). In Finland, the percentages of this disease by radiographic 
screening are high e.g. in: Golden Retrievers 27%, Berner Sennen dogs 
43%, Rottweilers 51% (Official Statistics of the Finnish Kennel Club 
1988-2007). 
The etiology of ED is on the whole unknown, but depending on which 
type of primary disease is referred to, genetic disposition, abnormal 
ossification, trauma, overloading due to overweight or exercise, possible 
malformation of the joint bone surfaces, nutritional excess, and metabolic 
reasons are all possible (Bennett & May 1995). 
chronic pain assessment in dogs2.2 
Since the first guidelines for recognition of animal pain (Morton & Griffiths 
1985, Sanford et al. 1986), the acceptance for animals experiencing 
subjective pain in a similar way as humans, has grown in recent years 
(ACVA 1998, Lascelles & Main 2002, Robertson 2002, Rutherford 2002). 
Canine pain behavior can be divided into three categories. The first 
category consists of genetically predisposed pain responses common for 
all dogs and most other mammals, such as avoiding the triggering pain, 
physiological responses (pupils, heart rate, breathing rate), and screaming 
with acute pain (Morton & Griffiths 1985, Sanford et al. 1986, ACVA 1998). 
There are, however, marked differences both between and within species 
in pain behavior (Sanford 1992, Dobromylskyj et al. 2000). In the canine 
species, human genetic manipulation through breeding has resulted in 
very different dog breeds with very different behaviors, characters and 
appearances, e.g. guard dogs, competing runners, shepherds, heelers, 
hunting dogs, and companion dogs. As a consequence, there are more 
typical pain responses related to different dog breeds than among the same 
species of other animals; certain dog breeds are more stoic, while others 
are “whimpers” (Dobromylskyj et al. 2000). Moreover, distinct individual 
differences exist (Dobromylskyj et al. 2000).
The second category contains socially acquired pain responses. As 
humans seem to learn their pain behavior from their parents at a very early 
age (Sargent & Liebman 1985), dogs may also learn their pain behavior 
from their owners, as they would have learned from their own species, 
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had they lived in a dog pack (Dobromylskyj et al. 2000). Some owners 
encourage their dogs to show pain, others do not. 
The third category of pain behavior is the ability to shift the two former 
pain responses. Dogs likely can set their behavioral patterns with such 
rigidity that these can override the genetic autonomic responses and 
muscle reactions normally triggered by pain (Wall 1992). These patterns 
can be used to show more pain – or less. All dogs can become “very lame“ 
if they learn that they will gain more attention and perhaps titbits from 
certain members of the family. On the other hand, a dog showing severe 
pain symptoms in a normal setting may show no signs of pain when, for 
instance, taken out for a hunt or to a clinic (Dobromylskyj et al. 2000, 
Flecknell 2000). 
Wall (1992) also points out the necessity of understanding a particular 
animal’s relationship with its environment at a particular time. The absence 
of the owner, the awkward smells, and the sounds of other animals may 
influence how or if an animal shows signs of pain (Dobromylskyj et al. 
2000). Because of this shifting of the dog’s pain responses, it has been 
suggested that the owner’s observations should be considered in pain 
assessment (ACVA 1998, Hardie 2000, Wiseman et al. 2001) and used to 
evaluate treatment outcome in clinical research. The owner has a closer 
relationship than the researcher with the animal and should therefore be 
able to detect subtle changes in the dog’s mood and behavior in the normal 
environment. When owners evaluate pain in their dogs, they work as 
“proxies” and they observe someone else’s pain using observational scales. 
As several researchers recently have pointed out, outcome based veterinary 
medicine still lacks reliable validated outcome measures (Schulz et al 2006, 
Cook 2007, Kapatkin 2007a). When this problem will be tended to, it will 
enable us to draw more accurate conclusions when evaluating different 
treatments, for example for painful musculoskeletal diseases such as 
osteoarthritis (OA). Therefore, it is of utmost importance to now validate 
and test reliability for old and new chronic pain outcome measures. 
pain scales2.2.1 
The scales used to assess pain in dogs are similar to those used in people: 
(1) visual analog scale (VAS); a response is indicated along a 10-cm 
continuum (Revill et al. 1976, Conzemius et al. 1997, Holton et al. 1998), (2) 
numerical/numeric rating scale (NRS), which has the numbers 1-10 written 
successively from left to right and where the assessor circles the number 
that seems to correspond best to his evaluation (Conzemius et al. 1997, 
Holton et al. 1998), (3) simple descriptive scales (SDS) which offer several 
(usually 3-5) written answers, often corresponding to degree of severity 
(Holton et al. 1998) - in some articles (e.g. Conzemius et al. 1997, Quinn 
et al. 2007) the term NRS has been used for questions that more typically 
would have been called SDS questions, which has lead to some confusion - 
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and (4) variable rating scale (VRS) (Hardie 2000), multifactorial pain scale 
(MFPS) (Firth & Haldane 1999, Dobromylskyj et al. 2000) and multifocus/
multifactorial descriptive scale (MDS) that are close to synonyms and all 
contain a number of SDS questions relating to different aspects of pain 
(Hardie 2000). Attempts have been made to compare various methods of 
scoring or assessing pain in dogs, especially acute pain that develops after 
surgery (Conzemius et al. 1997, Holton et al. 1998, Firth & Haldane 1999, 
Holton et al. 2001). The science that validates scales is called psychometric 
statistics (Streiner 1993). Before researchers use a test, they will want to 
know that it is both valid and reliable (Carmines & Zeller 1979) but thus far 
chronic pain outcome measures have been very sparsely evaluated. There 
are many ways to test this and no one single test can unequivocally “prove” 
its worth, but together, tests strengthen a scale or an index (Carmines & 
Zeller 1979). The methods chosen are partly due to how data is gathered 
and partly due to the researchers’ preference. A short description of the 
termes used is given in Appendix 1. Pain scales were first used only by 
medical personnel such as veterinarians and research nurses (Conzemius 
et al. 1997, Welsh et al. 1997, Holton et al. 1998, 2001, Firth & Haldane 
1999, Morton et al. 2005).
Observational VAS scale2.2.1.1 
The observational pain VAS has a single 10-cm continuum. The left endpoint 
signifies “no pain”, whereas the right endpoint signifies the “worst possible 
pain”. The observer places a mark on the line corresponding to his/her view 
of the patient’s pain intensity. The VAS pain score is the distance to the 
nearest millimeter, between the mark and the left end of the scale (Varni 
et al. 1987). In a human study, the VAS for constant or chronic pain was 
deemed reproducible, a good correlation existed between repeated ratings 
of a recalled pain distant in time, and changes in ratings were likely to be 
real changes of opinion (Revill et al. 1976). Because of its strengths as a self-
report measure, its ease of use, its good reliability and validity, its low cost, 
and its being a metric measure that enables parametric testing, the pain 
VAS was introduced for observational chronic pain assessment in human 
medicine (Varni et al. 1987, Huijer Abu Saad & Uiterwijk 1995). In a review 
(van Dijk et al. 2002) evaluating an observational pain VAS for pediatric 
pain assessment, with professionals and parents evaluating small children 
(resembling owners evaluating their dogs’ pain), the validity was evaluated 
and the correlation coefficient of the children’s self-rated VAS compared 
with the professional proxies VAS ranged from 0.23 to 0.85 (median 0.53) 
and compared with parents’ VAS it ranged from 0.46 to 0.83 (median 0.70), 
in relatively small samples (n=13-46). The correlation coefficients between 
the observational VAS and other pain instruments ranged from 0.42 to 0.86 
(median 0.68). Both parents and physicians tended to over-report chronic 
pain (Varni et al. 1987, Huijer Abu Saad & Uiterwijk 1995).
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Veterinarians and research assistants familiar with canine pain have 
used this human tool for acute and postoperative canine pain assessment 
in dogs (Conzemius et al. 1997, Holton et al. 1998) and chronic lameness 
in sheep (Welsh et al. 1993), but at the outset of our research we knew of 
no studies on an owner used pain VAS. Innes and Barr (1998) introduced 
an owner reported VAS tool for outcome assessment after knee surgery, in 
dogs.
Multifocus/multifactorial descriptive scale (MDS scale)2.2.1.2 
The MDS contains a number of SDS questions relating to different aspects of 
pain. Here different variables can have either the same or different weights 
(Hardie 2000). Wiseman et al. (2001) were the first to report a preliminary 
study involving unstructured interviews with 13 owners of dogs with 
chronic pain. All owners reported some changes in their dogs’ behavior 
and most reported some change in demeanor. Six veterinarians were also 
questioned about how they assess chronic pain, and they reported similar 
changes in canine behavior. Only recently have researchers validated owner 
used MDS scales. (Wiseman-Orr et al. 2004, 2006, Brown et al. 2007b). 
In a comparative MDS questionnaire, questions are posed to compare a 
variable with something, usually the baseline or the time before treatment. 
These typically include 3-5 answers on a scale of having changed for the 
better, stayed the same, or changed for the worse (Gibson et al. 1980, 
Bollinger et al. 2002, Väisänen et al. 2004, Pollard et al. 2006, Jaeger et al. 
2007). At the end of the trial period or at follow-up, questions regarding 
owner satisfaction or trial outcome has been used (Jaeger et al. 2007). Scales 
where the owners have to guess what treatment their animal received and 
questions about if owners would gladly continue their animals treatment, 
have also been used (Jaeger et al. 2007). 
need for rescue analgesia2.2.2 
As it is ethically necessary to alleviate severe pain, the amount of additional 
medication needed, often referred to as rescue analgesics, can be used 
as a measure of treatment success (Sanford et al. 1986, Innes et al. 2003, 
Hamunen & Kalso 2005). Drop-out rate has also been used as a measure of 
effectiveness in human studies (Caughey et al. 1983).
veterinary evaluation2.2.3 
Evaluating chronic pain due to OA in dogs has been done using very 
different means of measuring: Lameness and weight bearing are commonly 
used (Holtsinger et al. 1992, Vasseur et al. 1995, Borer et al. 2003, Peterson 
& Keefe 2004). Abnormalities of the locomotor system can be scored, for 
example, limb circumference as a measure of atrophy (Dobromylskyj et al. 
2000, Millis 2004), decreased limb range of motion (ROM) of extending 
or flexing joints (Holtsinger et al. 1992, Vasseur et al. 1995, Millis 2004), 
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swelling (Borer et al. 2003), crepitus (Holtsinger et al. 1992), pain from 
palpation (Holtsinger et al. 1992, Vasseur et al. 1995, Borer et al. 2003), 
or willingness to hold up a contralateral limb (Vasseur et al. 1995). No 
research showing validity or reliability of these methods is to our knowledge, 
available.
Hormones related to chronic pain2.2.4 
Concentrations of various hormones have been used to assess stress 
and pain in animals (ACVA 1998). Plasma adrenaline, noradrenaline, 
β-endorphin, cortisol, and vasopressin concentrations are known to 
increase in stressful situations such as trauma and surgery (Desborough 
2000). However, no information regarding the change in concentration of 
any of these hormones in response to chronic pain in dogs is available. 
In horses that were expected to have severe postoperative acute pain, 
β-endorphin concentration was shown to increase (Raekallio et al. 
1997). In a study by McCarthy et al. (1993), however, one control horse 
that suffered from painful chronic OA had decreased β-endorphin 
concentration. Almay et al. (1978) observed that organic pain in humans 
resulted in decreased cerebral spinal fluid endorphin concentrations. In 
Ley et al. (1992), sheep with chronic foot rot-associated lameness had 
increased plasma adrenaline and noradrenaline concentrations, compared 
with those of control sheep. In another study, the investigators showed no 
consistent changes in vasopressin concentration in chronically lame sheep, 
but cortisol concentration was decreased compared with controls (Ley et 
al. 1991). In a later study with a greater number of sheep, an increase in 
plasma cortisol concentration was noted in lame sheep, but no correlation 
was present between disease severity and cortisol concentration (Ley et al. 
1994).
radiographic changes 2.2.5 
It is generally accepted that the clinical status or the amount of pain of 
an animal cannot be predicted from the pathologic changes seen on 
radiographs (Dobromylskyj et al. 2000). Kealy et al. (2000) have shown 
that the most common finding in dogs with OA of the hip was periarticular 
osteophytes in the proximal aspect of the femur. At the time of our trial, 
we found no studies where radiographic changes within the coxofemoral 
or elbow joint would have been correlated with pain assessment scales. 
Recently some studies have been published on radiographic OA and limb 
function in the stifle (Gordon et al. 2003) and in the shoulder (Åkerblom 
& Sjöström 2007). Radiological abnormalities and changes in locomotion 
that result from chronic pain associated with disease of the hip joint in 
dogs are, however, well documented (Smith 1997, Slocum & Slocum 
1998). The radiographic features of advanced OA are well documented. 
This is the most commonly used method for diagnosing OA, showing joint 
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space narrowing, subchondral bone sclerosis, subchondral cyst formation, 
marginal osteophytes (Creamer & Hochberg 1997), joint deformity with 
preservation of articular margins, proliferative and lytic changes at the 
attachment sites of the joint capsule and the supporting ligaments, and 
partial to complete ankylosis (Gielen 2005). It is an excellent imaging 
technique for bony structures, but is poor for soft tissue structures. 
Another drawback is that as a two-dimensional technique it superimposes 
structures and can therefore mask marked changes (Gielen 2005). Plain 
radiographs can confirm a diagnosis, but the absence of changes does not 
exclude the presence of OA. Early OA is difficult to diagnose, as no visible 
radiological changes are yet apparent (Bennett & May 1995). 
Force plate as a measure of weight bearing2.2.6 
The most objective pain assessment method for dogs with chronic limb 
pain now available, is measurement of ground reaction forces (GRF) by 
force plate analyses, where it is postulated that a dog will put less weight 
on a limb if it is painful (Anderson & Mann 1994). Force plate analysis is 
viewed as the gold standard for evaluation of lameness (Quinn et al. 2007). 
The used force plates measure three orthogonal forces: mediolateral (Fx), 
craniocaudal (Fy, also referred to as the braking and propulsive force), and 
vertical (Fz, peak or mean vertical force [PVF] and vertical impulse). Dogs 
normally carry 60% of their bodyweight on the forelimbs and 40% on the 
hind limbs (Budsberg 1987).
The force plate has been used to evaluate GRF in dogs with CHD; 
these dogs have significantly reduced vertical forces in the hind limbs 
and stride length is increased, but velocity, maximal foot velocity, stance 
duration, and stride frequency do not differ between CHD and clinically 
normal dogs (Bennett et al. 1996). Force plate has been used to evaluate 
treatments of OA of the hip (Vasseur et al. 1995, Budsberg et al. 1996, 1999, 
2001, Moreau et al. 2003) and elbow joints (Bouck et al. 1995, Vasseur et 
al. 1995, Theyse et al. 2000, Moreau et al. 2003). The best variables for 
these conditions were considered to be PVF and vertical impulse. Vertical 
impulse was found to be a better indicator of improvement than the PVF 
and has often been selected as the primary response variable (Budsberg 
et al. 1996, 1999, 2001). Trotting velocities of 1.6-1.9 m/s (Budsberg et 
al. 1996, 1999, Kapatkin et al. 2007b), 0.8-2.1 m/s (Bennett et al. 1996), 
1.45-2.05 m/s (Trumble et al. 2004, 2005), 1.8-2.3 m/s (Allen et al. 1994), 
1.5-2.25 m/s (Jevens et al. 1996) and acceleration variation of ± 0.5 m/s2 
(Budsberg 1996, 1999, Kapatkin et al. 2007b) have been used. The mean of 
3-6 valid runs is typically used, as variation between runs can be very large 
(Jevens et al. 1996, Tano et al. 1998, Budsberg et al. 1999). To hide the force 
plate from the dogs, it is usually mounted into the floor or into a wooden 
walkway of 10-15 m that is covered with a rubber mat (Anderson & Mann 
1994). Photocells that measure velocity and acceleration are mounted 
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beside the walkway (Budsberg et al. 1999). When force plate analysis has 
been compared to other measures of treatment outcome the results have 
not always been equal; in a trial by Vasseur et al. (1995) owners evaluated 
38% of the placebo dogs to get better, veterinarians 26% of the dogs and the 
force plate showed 56% of the dogs to have become better. 
management of oa2.3 
So far, one should not talk about treating OA, but managing it, as no cure 
is known. A very early stage of OA has recently been identified where the 
disease process potentially still is reversible (Stoker et al. 2006). As a result, 
some researchers think that new therapies targeting the pathophysiology 
of OA will, with time, give us a definitive cure for OA (Pelletier et al. 2006). 
In the meantime, most doctors will use one of the two traditional ways to 
manage OA: pharmacological, using mainly NSAIDs or corticosteroids, or 
surgical (Kapatkin et al. 2002). However, since OA now is seen as a more 
complex ongoing process, a multimodal approach has been suggested and 
other approaches for different stages of the disease has also been introduced 
(Lascelles & Main 2002, Millis & Levine 2002, Pascoe 2002, Carmichael 
2005). All dogs with OA should also avoid overweight and have regular 
exercise (Brosseau et al. 2003b, Fransen et al. 2003, Carmichael 2005).
nonsteroidal anti-inflammatory drugs (nsAids)2.3.1 
Nonsteroidal anti-inflammatory drugs (NSAIDs) were introduced for 
veterinary use in the form of sodium salicylate at the end of the 19th century 
(Lees 2005). For canine OA, carprofen and meloxicam are the two NSAIDs 
mostly used at present. As carprofen was used in our studies, it will be 
presented here. 
Most NSAIDs inhibit the cyclooxygenase pathways COX-1 and COX-2 
(Fig. 3), one or both, but their exact mechanism of action is still not fully 
understood (Fox & Johnston 1997, Lees 2005). COX-1 inhibition produces 
toxic effects, as COX-1 is a constitutive enzyme present in most cells of the 
body. COX-1 is responsible for inhibition of synthesis of pro-inflammatory 
mediators, such as prostaglandin E2 (PGE2), and also for many physiological 
functions in the body, including gastro- and reno-protection and blood 
clotting. Current evidence suggests that up to 95% PGE2 inhibition may 
be required for effective suppression of lameness in OA dogs (Lees 2005). 
This COX-1 inhibition leads to potentially severe side-effects, such as renal 
toxicosis and irritation of the gastrointestinal tract, and possibly also to 
severe hemorrhagic ulcers and death (MacPhail et al. 1998, FDA 1999). 
In the 1998 annual report from the FDA in the United States, 43.4% of 
reports of adverse effects of drugs from all animals, indicated Rimadyl® 
(carprofen) for dogs as the suspected drug (FDA US ADE Report 1999). 
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Carprofen has also been found to trigger hepatic toxicosis, especially in 
Labradors (MacPhail et al. 1998). Other studies, however, have found no 
side-effects for carprofen (Holtsinger et al 1992, Raekallio et al. 2006). 
COX-2 inhibition produces therapeutic effects, as COX-2 is an inducible 
enzyme present at sites of inflammation and is responsible for producing 
pro-inflammatory mediators. COX-2 is also recognized as a constitutive 
enzyme in brain, kidney, ovary, uterus, ciliary body, and bone (Lees 2005). 
Complete inhibition of COX-2 over long periods might therefore lead 
to abortion, fetal abnormalities, delayed healing of bone and soft tissue, 
cardiovascular problems, and renal toxicity. The cardiovascular events in 
humans due to COX-2-inhibiting NSAIDs support this speculation (Lees 
2005). Further, COX-1 has been suggested to contribute to the synthesis 
of pro-inflammatory PGs. Both COX-1 and COX-2 inhibition might 
therefore be required for optimal efficacy (Lees 2005). 
A newer type of NSAID is the dual inhibitor, inhibiting both COXs and 
5-lipoxygenase (also referred to as 5-LO, 5-LOX, or LOX), thus blocking 
the synthesis of both PGs and leukotrienes. Its advantage is greater 
gastrointestinal, hepatic, and renal tolerance (Lees 2005).
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Fig. 3. The points of action for some chondroprotective and anti-inflammatory 
products (compiled from research findings presented in the text). 
Variation in pharmacokinetics and pharmacodynamics between dog 
breeds and individual animals occurs between drugs but also for the same 
drug, explaining the individual differences commonly encountered by 
clinicians and owners in therapeutic response and tolerance (Lees 2005). 
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Carprofen triggers a clinical response very quickly, that vanishes rapidly 
upon discontinuing the drug, as the half-life is merely 8 hours (Fox & 
Johnston 1997). 
disease-modifying oA drugs (dmoAd)2.3.2 
OA is still a non-curable disease that gradually deteriorates to an end-stage 
disease. It is important to intervene as early as possible to reduce escalation 
of the pathology as the more advanced the condition is, the more difficult it 
is to treat (Carmichael 2005). As the pathophysiological events associated 
with OA are becoming increasingly understood, new therapies that target 
a specific pathway have emerged (Pelletier et al. 2006). Articular cartilage, 
subchondral bone, synovial fluid, and synovium of affected joints can be 
modified with “slow-acting drugs of OA”, “disease-modifying agents” or 
“disease-modifying osteoarthritis drugs” (DMOAD) (Carmichael 2005, 
Aragon et al. 2007).
The most attractive new therapeutic targets for the development of 
DMOAD are (1) cytokines (especially IL-1β) (Fig. 2), NO, reactive oxygen 
species and eicosanoids (Fig. 3) to target the inflammatory process, (2) 
MMP-13 and Aggrecanase-2 to target cartilage degradation and (3) 
biophosphonates to target subcondral bone remodelling (Pelletier et al. 
2006). Glasson et al. (2005) showed that deletion of active ADAM-TS-5 
prevents cartilage degradation in a murine model of osteoarthritis. In gene 
therapy OA can be treated by controlling the expression of a number of 
genes that are responsible for the synthesis of factors involved in cartilage 
degradation and/or those that promote cartilage repair (Gelse et al. 2005). 
Chan et al. (2006) showed that glucosamine and chondroitin sulfate in 
vitro inhibit the expression of MMPs and ADAM-TSs and increase the 
expression of one of their natural inhibitors, TIMP-3. 
Evidence has implicated IL-1β as being the principal cytokine 
responsible for the signs and symptoms of inflammation in OA (Goldring 
& Goldring 2004). Compounds like rhein (from diacerein) that inhibit 
IL-1 synthesis and activity have shown improvement of OA symptoms as it 
reduces articular cartilage damage (Pelletier et al. 2000). MMP inhibitors 
such as doxycycline are currently tested for OA indications (Brandt et 
al. 2005). Medications that have a bone anti-resorptive effect (oestrogen, 
raloxifene and alendronate) have been tested for OA but the results are still 
unconclusive (Pelletier et al. 2006).
Another target is boosting components of cartilage matrix. In the 
form of injections given parenterally, polysulphated glycosaminoglycans 
(PSGAG), hyaluronic acid and Ca- or Na-pentosan polysulphate has been 
studied on dogs (DeHaan et al. 1994, Aragon et al. 2007, Budsberg et al. 
2007). Peroral alternatives include nutraceuticals that mainly work through 
glycosaminoglycans (GAG) or their components, vitamins, minerals, and 
polyunsaturated fatty acids (PUFA) (Bauer 2001, Aragon et al. 2007). Of 
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the five GAGs present in cartilage tissue, chondroitin sulphate (primarily 
extracted from shark, bovine, or poultry tissues and green lipped mussel) 
or its constituent glucosamine (primarily extracted from chitin; the 
exoskeleton of crabs, shrimps, lobsters in the form of glucosamine sulphate 
or hydrochloride) are the most commonly used, together with omega-3 
fatty acids (n-3 PUFAs) (Curtis et al. 2004). Glucosamine hydrochloride 
is readily absorbed in the intestine (up to 98%) (Senikar et al. 1986). 
Glucosamine sulphate has been shown to reduce symptoms of OA in 
humans in both single-blinded (Crolle & DiEste 1980, D’Ambrosio et al. 
1981) and in experimental or double-blinded trials (Drovanti et al. 1980, 
Pujalte et al. 1980, Reichelt et al. 1994, Qiu et al. 1998, Clegg et al. 2006) and 
in dogs (Johnson et al. 2001, McCarthy et al. 2007). One trial has reported 
no effect in humans (Rindone 2000) and one in dogs (Moreau et al. 2003). 
In a Cochrane review of human RCTs where glucosamine was compared 
to NSAIDs, glucosamine was found to be superior in two and equivalent 
in two (Towheed et al. 2003). Chondroitin sulphate has been shown to 
reduce pain, increase joint mobility, and induce healing of the joints of 
people with OA (Pipitone et al. 1992, Morreale et al. 1996, Uebelhart et al. 
1998, Verbruggen et al. 1998, Clegg et al. 2006). The role of PUFAs will be 
reviewed under GLM.
Green lipped mussel (GLM) 2.3.2.1 
The green lipped mussel (GLM) is a DMOAD with multiple targets. 
However, its mechanism of action is not entirely understood (Servet et al. 
2006). GLM products are a rich source of nutrients, including GAGs, such 
as chondroitin sulphates, vitamins, minerals, and omega-3 series PUFAs 
(Halpern 2006) (Table 1). 
Table 1. Content of a 100% GLM product, typical analysis. 1 capsule often contains 500 
mg. (Technyflex/Lyproflex test certificate 2002)
~50% protein 
~10% fat
 Total Omega-3s: 18 mg/1 g, here the 3 main ones:
 1 mg eicosatetraenoic acids (ETA)/1 g 
 8,8 mg eicosapentaenoic acid (EPA)/1 g           the n-3 PUFAs
 5,5 mg docosahexaenoic acid (DHA)/1 g
~17 % carbohydrates
 Proteoglycans 30%. GAGs: 11-15%, predominantly chondroitin  
 sulfate 
~5% moisture 
~18 % ash
Minerals: B, Ca, Cu, Cr, I, Fe, Mn, Mg, K, P, Na, S, Se, Ta, Zn
Vitamins: A, D, E, B2, B3, B6, B12, C
}
34
The potent anti-inflammatory activity of GLM powder was confirmed in 
vivo using the established rat paw edema model; rats fed mussel lipids per 
os developed neither adjuvant-induced polyarthritis nor collagen-induced 
auto-allergic arthritis (CIA) (Rainsford & Whitehouse 1980, Whitehouse 
et al. 1997). However, these lipids showed only marginal inhibition of 
carrageenan-induced paw edema in rats (acute irritation assay, which is the 
standard test for NSAIDs), indicating that they do not mimic rapid-acting 
NSAIDs (Whitehouse et al. 1997). Macrides et al. (1997) found that the 
eicosatetraenoic acids (ETA) of GLM had considerable anti-inflammatory 
activity. In vitro, the extracted lipids have been shown to possess significant 
COX and LOX inhibitory activity (Whitehouse et al. 1997) (see Fig. 3, page 
31). Recently, new GLM extracts were tested, and the Tween-20 extract 
(extracted by a cationic detergent) was noted to effectively inhibit both 
COX-1 and COX-2 cyclooxygenase activity (Mani & Lawson 2006). It 
also decreased IgG levels and induced a significant reduction in TNF-α, 
IL-1, IL-2, and IL-6, as observed using cytokine bioassays. The active 
components were found to possess a molecular weight above 100 kDa. GLM 
was suggested to mediate T-helper cell (Th1/Th2) regulation as it relates 
to inflammation, therefore playing an immunomodulatory role (Mani & 
Lawson 2006). In a recent study, they observed dose-dependent reduction 
in TNF-α and IL12-p40 production and in neutrophil superoxide burst 
activity, in Perna treated cultures (Lawson et al. 2007). In the in vivo part 
of this same study, significant amelioration of mouse CIA and significant 
reduction in disease incidence, onset, and severity of rat CIA was noted 
in the Perna groups of animals, compared with controls (Lawson et al. 
2007). 
GLM is reported to have no severe side-effects (Cleland et al. 1988, 
Gibson & Gibson 1998, Cho et al. 2003), but has rarely caused some fluid 
retention, epigastric discomfort, nausea or a transient aggravation of 
symptoms in some human patients (Brooks 1980, Gibson et al. 1980, 1998). 
In newer trials no side-effects have been reported, which might indicate 
that the newer products are better tolerated (Pollard et al. 2006). In fact, 
research suggests that GLM may have chondroprotective properties due 
to its GAG, especially chondroitin sulphate, content (Bassleer et al. 1992, 
Korthauer & Torre 1992, Bucci 1994). Unlike with the use of NSAIDs, 
platelet aggregation is unaltered and the lipid fraction is nongastrotoxic in 
fasted disease-stressed arthritic rats even at a dose of 300 mg/kg (equals 15 
x treatment dose) (Rainsford & Whitehouse 1980, Whitehouse et al. 1997), 
indicating that they inhibit predominantly the COX-2 pathway (Mani & 
Lawson 2006). 
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Homeopathy 2.3.3 
Investigations whether, and if so, how, homeopathy works, are beyond 
the scope of this thesis, but some basics will be reviewed here. Two 
principles make a treatment homeopathic: (1) the underlying idea is to 
treat a disease symptom with a preparation of a natural substance, or a 
combination of them, that in itself could give a healthy patient the same 
symptoms (similia, the “same” principle; e.g. treating sleeplessness with 
coffee) (Bellavite et al. 2005, Hektoen 2005), and (2) the preparations 
are diluted using a certain method, potentizing, which means that they 
are repeatedly diluted and between every dilution the remedy is shaken 
vigorously. D potencies are diluted 1:10 and c-potencies, 1:100. For 
example, D4 is diluted 1:10 four times, and shaken 60 times between every 
dilution (Bellavite et al. 2005, Hektoen 2005). The final products will have 
an estimated molar concentration of a substance of 10-1 mol/l, and up to 
10-2000 or more. Thus, a range of homeopathic remedies exist, where at one 
end dilutions actually include measurable amounts of a substance and at 
the other end dilutions most likely will not contain a single molecule of the 
substance (Hektoen 2005). Thus, the distinction between low and high-
dilution effects is important where both fields fully belong to homeopathy, 
provided that the medicine is prescribed according to the similia principle 
and according to a holistic clinical approach (Bellavite 2006b). The very low 
substance concentration of the high-dilution remedies is the reason why 
occidental medicine has trouble understanding how homeopathy could 
work (Bellavite et al. 2005, Hektoen 2005). The other aspect of homeopathy 
that worries conventional scientists, is the claim that the more potentized, 
i.e. diluted, the remedy is, the more powerful are the treatment effects of it 
(Bellavite 2006c). Low homeopathic dilutions in the range of D1-D20 (up 
to 10c) may theoretically work like the extremely low concentrations (10-10- 
10-20 mol/l) that have been shown to be biologically active in “conventional” 
biochemistry and immunology (Eskinazi 1999, Bellavite 2006b).
A multitude of studies with observations that are consistent with positive 
homeopathical effects, have been published during the last 15 years. A 
multicenter study from four different laboratories in four countries has 
reported consistent results; high dilutions of histamine (10-30-10-38 mol/l) 
influence the activation of human basophils measured both by alcian blue 
staining and flow cytometry (Belon et al. 1999, 2004). The degree of this 
inhibition depended on the initial level of anti-IgE-induced stimulation, 
with the greatest inhibitory effect seen at lower levels of stimulation 
(Belon et al. 1999, 2004). Another study showed that very small amounts 
of hemocyanin antigen (10-36 M) were capable of significantly increasing 
a specific IgG response in mice (Wiseman et al. 1991). A carragenan-
induced rat paw edema was significantly inhibited in rats treated with 
Causticum 6c, 12c, 30c, and 200c dilutions compared with untreated 
rats (Prado Neto et al. 2004). When the conventional anti-inflammatory 
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agent dexamethasone was diluted to 7c and 15c (equivalent to 10-17 and 
10-33 mol/l), these homeopathic dexamethasones partially blocked the 
anti-inflammatory effect of pharmacological dose dexamethasone with 
regard to paw edema and polymorphonuclear cell migration into the 
peritoneal cavity, both significantly (Bonamin et al. 2001). A recent study 
showed that mice fed a daily drop of homeopathic Arsenicum Album 200 
(diluted 200 times 1:100, 10-400) showed significantly reduced toxicity of 
induced chronic arsenic poisoning in all studied parameters, compared 
with controls (Banerjee et al. 2007). These results suggest that a potentized 
substance may have both effects opposite to its own pharmacological 
effects, thus supporting the similia principle, and also, that high dilutions 
act on specific parameters of host response (Bonamin et al. 2001). In most 
of the studies mentioned above, the dilutions were lower than 10-24, which 
according to Avogadro’s law should contain, on the average, at most one 
molecule of active principle per liter (Bellavite 2006b). Also, in all the cited 
studies the authors were unable to explain the method of action for these 
results and they also acknowledged that, in view of the vast implications 
of these findings, the experiments should be rigorously repeated and 
confirmed (Wiseman 1991). 
Also, it is difficult to reject homeopathy outright since meta-analyses 
evaluating homeopathic studies have found significant differences between 
homeopathic and placebo groups, favoring homeopathy (Kleijnen et al. 
1991, Linde et al. 1997, Shang et al. 2005). A complete review of homeopathy 
is available in Bellavite et al. (2005, 2006a,b,c,d,2007).
Homeopathic combination preparation (HCP) Zeel® ad us vet.2.3.3.1 
Homotoxicology or anti-homotoxic medicine was developed from 
homeopathy in the 1980s in Germany (Reckeweg 1981). Although the 
homotoxicological remedies are somewhat different from other complex 
homeopathic products, they are recognized as “homeopathic remedies” by 
the EU drug legislation (Bellavite et al. 2006c). The term “homotoxins” is 
used for all substances, both exogenous and endogenous, that are harmful to 
man or animal. Homotoxicology uses lower dilutions (D2-D10) than those 
usually used in classical homeopathic remedies and are often combination, 
or complex, products (Heel 2000). Zeel® ad us vet. is a combination 
preparation with 14 low-dilution (D2-D8) ingredients (Table 2) and is 
used on arthropaties in e.g. horses and dogs (Boyeux 1984, Faulstich et al. 
2006, Neumann et al. 2007). This product contains specific homeopathic 
substances as well as specific anti-homotoxic substances such as potentized 
suis-organ parts (homeopathically potentized organ parts from swine, 
representing iso-organotherapy), catalysts, and nosodes (meaning any 
remedy extracted from pathological tissues or microbial products) (Heel 
2000, Bellavite et al. 2005). 
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Table 2. Content of Zeel® ad us vet.
The content of one 5.0 ml ampoule of the low-dilution homeopathic combination 
preparation (HCP): Zeel® injection solution. The third column indicates dose (mg) of 
the different dilutions in the ampoule, the fourth is dose of actual dry matter (DM) in 
one ampoule (Dil = D2-D8 = diluted 1:10 two to eight times). From the Heel Company 
Veterinary Guide, Baden-Baden, Germany, 1997 and from technical support.
Zeel® ad us vet.
5 ml ampoule
Dil mg
dil.
mg
DM
Cartilago suis D6 5.0 5 x10-6
Funiculus umbilicalis suis D6 5.0 5 x10-6
Embryon totalis suis D6 5.0 5 x10-6
Placenta totalis suis D6 5.0 5 x10-6
Solanum dulcamara D3 25.0 7.5 x10-4
Symphytum officinale e radice D6 25.0 5 x10-7
Nadidum D8 5.0 5 x10-8
Coenzyme A D8 5.0 5 x10-8
Sanguinaria canadensis D4 7.5 1.4 x10-5
Arnica montana D3 50.0 4.5 x10-4
Sulfur D6 9.0 9 x10-6
Natrium diethyloxalaceticum D8 5.0 5 x10-8
Acidum alpha-liponicum D8 5.0 5 x10-8
Toxicodendron quercifolium 
e summitatibus rec 
(=Rhus Toxicodendron) 
D2 25.0 1.2 x10-2
Research has attempted to enlighten the mechanisms of action of different 
human Zeel® preparations and their constituents. In a randomized, sham-
controlled placebo study on rabbits with experimentally induced knee OA, 
a significant difference in gross morphology and in a histopathological 
score was found in the joints treated with the HCP Zeel® Comp compared 
with untreated joints (Stancikova et al. 1999a). In an in vitro study, cartilage 
slices incubated for six days in a medium containing Zeel® showed better 
preservation of structure than controls, based on methods of interference 
polarization microscopy and x-ray difractometry for analysis (Orlandini 
et al. 1997). A reconstituted Zeel® comp. N combination as well as its 
constituent mother tinctures showed distinct inhibitory effects on the 
production of leukotriene B4 by 5-lipoxygenase (5-LOX) and on the 
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synthesis of prostaglandin PGE2 by COX-1 and COX-2 enzymes (Fig. 3, 
page 31) (Jäggi et al. 2004). This dual inhibition of both LOX and COX 
metabolic pathways may offer an explanation for the reported clinical 
efficacy and favorable gastrointestinal tolerability of the original Zeel® 
comp. N remedy (Jäggi et al. 2004). An in vitro study (Stancikova 1999b) 
demonstrated that two of the ingredients in the present test product were 
able to inhibit leucocyte elastase activity; Arnica D4 up to 70% and Rhus 
Toxicodendron D3 up to 77%. In a second study, Rhus Toxicodendron at D1 
and D2 potencies, as well as ten other plant extracts, were shown to inhibit 
cell growth of human cutaneous F54 fibroblasts (Valentiner et al. 2003). 
As a low-dilution product Zeel® ad us vet. contains measurable amounts of 
dry matter of eg. Rhus Toxicodendron, and may therefore be active due to 
working mechanisms similar to any other drug. 
Acupuncture 2.3.4 
Acupuncture is an old Oriental technique that has been used on humans 
in China, Japan, and Korea for at least 5000 years (Ma et al. 2005), but it is 
possible that it has been used as long in Europe. “Özzi”, the stone-age man 
that died 5200 years ago and recently was discovered in an Austrian glacier, 
had marks from burning the skin at acupoints, a technique still used in 
the orient (Dorfer et al. 1999). As Özzi was radiographed, he was found to 
have suffered from lumbar, knee and hip arthrosis and his colon was full of 
whipworm eggs. The points tattooed on his body were the same ones that 
one would still use to treat arthrosis and abdominal disorder. If the marked 
points really were used for treatment, it indicates that acupuncture was 
used also in Europe 5000-6000 years ago (Dorfer et al. 1999, Kothbauer 
2004). 
Acupuncture is currently used to treat many different diseases; in 1996 
WHO listed more than 40 indications for treating humans with acupuncture 
but they have now reduced them to the same 13 indications that FDA 
lists (NIH Consensus Conference 1998, WHO 2003). Acupuncture is 
considered a good treatment for canine OA (Janssens 1976, Schoen 2001). 
The curative duration of an acupuncture needling can vary from a few 
hours to a number of years but must eventually be repeated to keep the 
patient symptom-free (Klide 1992). Treatments can be given either using 
traditional metal acupuncture needles or by stimulating the points by 
electrical current (EA), laser, injecting substances, or implanting foreign 
material (Altman 2001).
The acupuncture point charts available for dogs were created in the 
1970s by the International Veterinary Acupuncture Society (IVAS) and are 
more or less directly superimposed from the human point charts (Janssens 
& Still 1985). 
The anatomy of the acupoint permits an induced electrical current to 
preferentially flow through that point, meaning increased local conductivity 
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(Reichmanis 1975, 1979). A specially designed “ohm-meter” can be used 
to find acupuncture points as electrical searching for acupuncture points 
is based on the principle of the Wheatstone bridge (Burns & MacDonald 
1975). The majority of acupoints have been shown to have low direct current 
resistance (50.000 ohms) and to be bilaterally symmetrical, compared with 
nonacupuncture points (200.000 – 2 million ohms) (Zhang et al. 1988, 
Xie et al. 1994, Pomeranz 1998). Based on anatomical findings 99.7% of 
acupoints are found in close proximity to peripheral nerves, 93.8% are 
related to superficial nerves, and 52.5% are related to deeper nerves (Zhao 
et al. 1993). Many acupuncture points are situated over a nerve, an artery, 
and a vein that travel together in a connective tissue shaft (Kothbauer 
2004). Janssens et al. (1987) showed that at least some acupuncture points 
are not situated exactly at the same anatomical site in all individual dogs. 
The mechanisms of acupuncture have been studied for over 30 years 
now. There are hundreds of studies and books that cover acupuncture 
analgesia and therefore it is covered only shortly in this text (for reviews, 
see Steiss 2001, Wynn et al. 2001, Cho et al. 2001, Ma et al. 2005). The 
six main mechanisms of acupuncture-induced analgesia are: (1) while the 
acupuncture needle insertion is stimulating the acute pain A-delta nerve 
fibers, interneurons block the C-fibers that carry chronic pain, thereby the 
perception of the chronic pain is not brought up to consciousness as both 
pain signals cannot be registered by the cortex at the same time. This is 
called the “pain gate theory” (Melzack & Wall 1965, Melzack & Casey 1968), 
(2) the acupuncture needle activates the GABA inhibitory receptors and 
the endogenous pain inhibitory system as well as other neurotransmitters 
(serotonin, noradrenaline etc.), which alter the processing of noxious 
information from A-delta and C fibers at various CNS levels (Pomeranz 
1998), (3) the endogenous opioids (endorphins, dynorphins, enkephalins 
etc.) act as analgesics but are 10-200 times stronger than morphine 
(Pomeranz 1998), (4) segmental acupuncture analgesia is localized, with 
rapid onset and disappearance and not necessarily needing the higher brain 
centers. It is evoked by high freequecy, low intensity stimulation of A-delta 
and C fibers, (5) there are hundreds of active endogenic substances that 
increase or decrease locally after introducing an acupuncture needle into an 
acupoint, substances (such as bradykinin, histamine, prostaglandins etc.) 
that have an impact on nociceptive excitation, vasodilatation, solubility, 
inflammation, tissue repair etc. (Kendall 1989) and (6) as pain perception 
now can be visualized with the help of functional magnetic resonance 
imaging (f-MRI): The acupuncture needle induces a reduction of brain 
activation in the hypothalamus and in the limbic system; bilaterally in 
Brodman area 24b (rostral part of anterior cingulate cortex, a key modulator 
of the internal emotional response to pain), ipsilaterally in 11 (orbital and 
basal gyri), bilaterally in the hippocampal complex and contralaterally in 
the amygdala formation. An increase in activity is seen in the contralateral 
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hypothalamus and nucleus accumbens, Broadman areas 8, 9 (prefrontal 
cortex) and 40 (parietal operculum) (Wu et al. 1999). 
Ha (1981) demonstrated that the analgesic effect of acupuncture could 
be reversed by the opiate antagonist naloxone, by infiltrating the stimulated 
acupoint with a local anesthetic, by interruption of the dorsal part of the 
lateral funiculus at the upper cervical level or by ablation of the postcentral 
gyrus, indicating that the neural mechanisms in acupuncture analgesia take 
place at various levels in the nervous system (i.e. the spinal cord, thalamus, 
and cerebral cortex). 
A recognized problem concerning placebo groups in acupuncture 
trials is that needling a nonacupuncture point may give the same kind of 
responses as needling a true acupuncture point (Debreceni 1993). There 
have been many studies that have researched into these mechanisms. 
Diffuse noxious inhibitory control (DNIC) was described in 1995 as a non-
acupoint stimulus that activates the same mechanisms as acupuncture at 
a traditional acupoint (Helms 1995). Here activity is probably triggered in 
descending pathways originating from the nucleus raphe magnus (Helms 
1995). The pain inhibition varies directly with the stimulus intensity; it 
appears to hyperstimulate a large population of A-delta and C fibers and 
persists after stimulation ceases (Helms 1995). It is not somatotopically 
organized, but triggered by a noxious stimulus from any part of the body 
(LeBars et al. 1979). “Hyperstimulation analgesia” is where either a strong 
sensory stimulus or one in the painful area can relieve pre-existing pain 
(Hoopwood et al. 1997), and “stress analgesia” is at least partly mediated by 
pituitary β-endorphins (Helms 1995, Pomeranz 1998). In a recent f-MRI 
study, sham acupuncture of nonacupoints led to a reduction of f-MRI 
activation in the same brain areas affected by needling a meridian acupoint 
(Cho et al. 2002a,b). Both stimulations reduced activation in the brain 
areas involved in pain perception, meridian acupuncture more than sham 
acupuncture but both significantly less than the pain stimulus by itself 
(Fig. 4). After these f-MRI studies, it is evident that one should not use any 
type of needling anywhere as a placebo (Cho et al. 2002a,b). This question 
of appropriate sham procedures and controls for acupuncture studies has 
frequently been discussed in papers by acupuncture researchers and critics 
alike (Ter Riet et al.1990, NIH Consensus Statement 1998, Pomeranz 1998, 
White & Ernst 1999, Paterson & Dieppe 2005).
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Figure 4. Side-by-side comparison of two cortical activations seen at mid-line sagittal 
view, at 4 different times, during two experiments. (a) Pain stimulation alone and 
meridian acupuncture (at acupoint LI 3) together with pain stimulation. (b) Pain 
stimulation alone and sham-acupuncture together with pain stimulation. Pain stimulus 
was given at time d=±0s. 
Published with the permission of the authors and the journal (Cho et al. 2002b).
Regarding inflammation, acupuncture was indirectly shown to significantly 
increase T cell, macrophage, B cell and NK cell activity, but this study had no 
placebo group and was not blinded (Yamaguchi et al. 2007). These findings 
indicate that acupuncture may regulate the immune system and promote 
humoral and cellular activities as well as NK cell activity (Yamaguchi et al. 
2007). Electroacupuncture and to a lesser degree dry needle acupuncture 
at an acupoint in the knee (acupoint ST36) significantly reduced CIA 
incidence, and IL-6, TNF-a, IFN-γ, collagen II antibody, IgG, and IgM 
levels in CIA mouse serum, and prevented knee joint destruction (Yim 
et al. 2007). These results indicate that EA (and dry needling to a lesser 
extent) has anti-inflammatory, anti-arthritic, and immunoregulatory 
effects on CIA in mice (Yim et al. 2007). 
Gold implantation in acupuncture points of the hip2.3.4.1 
In the early 1970s Dr Grady Young began experimenting with implanting 
acupuncture points in dogs to get longer lasting analgesic effects. Durkes 
was, however, the first to report on this method (Durkes 1989, 1992, 
1994). The gold “beads” to be implanted are either manufactured gold 
beads or 1-mm-diameter 24-carat gold wire that is then cut into 2-mm 
pieces (Klitsgaard 1995). The “ohm-meter” can be used to find the sites 
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for the gold to be implanted. Most dogs have three reactive points per hip, 
approximately in the same locations in different dogs. These points coincide 
with the three acupuncture points GB29, GB30, and BL54 (Durkes 1994, 
Klitsgaard 1995). Several studies without control groups have indicated 
success rates of 80-99% (Durkes 1989, 1994, 1999, Klitsgaard 1995, 1996, 
Thoresen 1996, Kothbauer 1997, Schultze 1998, 1999, 2001). 
The working mechanisms of gold implants are not entirely understood. 
Research covering the analgesic and anti-inflammatory effects of 
acupunctures stimulation was reviewed above (pp. 39-41). Gold as an 
active material also seems to play a role (Danscher 2002). Gold, e.g. various 
gold-thio compounds such as injectable gold sodium, has been shown to 
suppress inflammation in rheumatic joints (Empire Rheumatism Council 
1961). Already in the 1960s, gold was suggested to inhibit the lysosomal 
enzymes of phagocytotic cells in inflamed synovial tissue (Persillin & 
Ziff 1966). Gold ions are known to inhibit antigen processing and to 
suppress NFκB binding activity and IκB-kinase activation, resulting in 
a reduced production of pro-inflammatory cytokines (Yang et al. 1995, 
Traber et al. 1999, Yoshida et al. 1999). Danscher (2002) studied rats that 
had been implanted with 24 carat gold implants in different parts of the 
organism including the brain. After survival times from a few days and 
up to several weeks the tissue adjacent to the implants was analyzed with 
1) autometallography (AMG), a histochemical technique that makes it 
possible to trace particles of gold only a fraction of a nanometer in diameter 
and with 2) particle induced x-ray emission (PIXE). He found that gold 
ions are released from metallic gold surfaces by a process later coined 
dissolucytosis (Larsen et al. 2007). This bio-release of gold ions takes place 
both in vivo and in vitro when macrophages are exposed to metallic gold 
(Danscher 2002, Larsen et al. 2007). It has been shown by AMG that in rats 
exposed to gold compounds such as aurothiomalate, gold ions accumulate 
in a multitude of cells including macrophages and cells of the proximal 
tubule. The gold ions can be traced ultrastructurally in lysosomes by AMG 
(Danscher 1981, Danscher and Stoltenberg 2006). The dissolucytotic 
released gold ions are taken up by the macrophages themselves and also 
by mast cells and fibroblasts adjacent to the gold implant. As gold ions 
are known to be anti-inflammatory, Danscher suggest that metallic gold 
implants might have an important clinical aspect. He found that the bigger 
the surfaces of the gold implants, the more gold ions were released and the 
further away gold-loaded cells could be found (Danscher 2002). 
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OBJECTIVES OF THE STUDIES 3. 
The primary goal of this thesis was to expand our knowledge about 
unconventional treatments for canine OA. To be able to evaluate treatment 
outcome, we also had to assess different means of evaluating chronic 
canine pain, as no validated pain measurements yet existed at the time of 
the studies.
Specific aims of the study were as follows:
1. To develop methods for assessing chronic OA pain and OA treatment 
outcome in dogs. 
2. To test the validity and reliability of a multifactorial descriptive scale 
- the Helsinki chronic pain index (HCPI). 
3. To evaluate the following three complementary therapies in the treatment 
of chronic canine OA using randomized, controlled, double-blind study 
designs:
 - gold implants in acupuncture points, 
 - green lipped mussel per os,
 - homeopathic combination product per os.
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MATERIALS AND METHODS4. 
The following text will refer to two trials (1 and 2) and five publications 
(Studies I-V).
A summary of the work performed is presented in Table 3.
Dogs4.1 
Inclusion and exclusion criteria were very similar in all clinical trials (I-V). 
Inclusion criteria were that dogs had clinical signs and a radiographic 
diagnosis of OA in either a hip joint (I-V) or an elbow joint (II, IV,V). 
The owner had to have described at least two of the following signs as 
being frequent: difficulty in lying down and/or in getting up from a lying 
position, difficulty in jumping or refusing to jump, difficulty in walking up 
or down stairs, or definite lameness. Exclusion criteria were: inadequate 
clinical symptoms, systemic or infectious disease, neurological deficits, 
lameness from articular infection, or recent trauma. In trial 2, no hip-
operated dogs were allowed. There was no restriction regarding uni-or 
bilateral OA and the lameness could be all from non-existent to severe. 
All dogs were otherwise determined to be in good health based on history, 
physical, neurological and orthopedic evaluations, and serum biochemical 
analysis. 
Trial 1: Forty-one dogs, all of which were used in a study where different pain 
measurements were assessed (I) and 38 of which were included in a clinical 
trial where gold was implanted near the hip joint (III), randomizing them 
into either a treatment group (n=19) or a placebo group (n=19). Altogether 
24 healthy large or giant breed dogs with no history of pain were included 
in trial 1 as controls for the pain questionnaire (I) and another 23 similar 
dogs were used as a control group for plasma hormone analyses (I). 
Trial 2: Sixty-one dogs that had two baseline evaluations and that had not 
changed pain medication by more than one degree on the medication scale 
between evaluations, were used to assess an owner-evaluated chronic pain 
index (II). For the index responsiveness assessment, a cohort was picked 
after unblinding: The “medicated” group comprised NSAID-treated dogs 
(n = 13), and the “placebo” group (n = 11) comprised dogs that had taken 
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a placebo but no NSAIDs throughout the study period (II).
Altogether 44 (IV) and 45 (V) dogs finished the clinical studies of the 
green lipped mussel product Lyproflex (IV) and the homotoxicologic drug 
Zeel® (V), respectively. The dogs were divided into two treatment groups 
(n=15 and n=14), a positive control group (n=15), and a placebo group 
(n=15). All dogs had either moderate (grade D) or severe (grade E) changes 
in the worse affected hip joint or moderate (grade II) or severe (grade III) 
changes in the worse affected elbow joint (FCI 1991). 
Study protocols4.2 
All trials (III-V) were designed as randomized, controlled, double-blind 
clinical trials with the help of several guidelines and recommendations 
(Altman 1990, Shott 1990, Budsberg 1991, Begg et al. 1996, Scheinin 1997, 
Farrar et al. 2000, Moher et al. 2001, Asai 2002, MacPherson et al. 2002, Turk 
& Dworkin 2004). All evaluators (veterinarians and owners) and technical 
assistants were blinded, and the dogs were assigned to groups using 
computer-generated random lists (III-V). For ethical reasons, all owners 
were also given an extra rescue NSAID (meloxicam [III] or carprofen 
[IV,V]) at the start of the trial to use for the dog if pain was overwhelming. 
No other pain treatments were allowed. The amount of rescue NSAIDs 
used was recorded (III-V) using the following rating: “during the last four 
weeks additional carprofen was given 1 = not at all, 2 = 1-2 times/4 weeks, 
3 = about once a week, 4 = about 3-5 times a week, and 5 = daily/almost 
daily”. 
Owners of all dogs were required to sign informed consent forms. 
The trial protocols (I-V) were approved by the Ethics Committee of the 
University of Helsinki. 
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Table 3. Number of dogs, examinations, samples, and types of investigations, in all 
studies (n= number of animals, nq= number of dogs in the questionnaire control group 
nb = number of dogs in the blood sample control group, N= number of investigations 
performed, A= performed under anesthesia).
STUDY 
(trial)
Dogs Samples, examina-
tions, treatments
N investigation A
I (1) n=41 Clinical examinations  161 Rectal temperature  
nq=23  161 Palpation  
nb= 24  161 Lameness exam
III (1) n= 38 161 Jumping onto table
 161 Climbing stairs
161 Hip function (ROM)
41 Orthopaedic examination
 41 Neurological examination
Radiology 82 Official hip radiograph x
8 Others, when needed x
Plasma samples 65 Adrenaline
65 Noradrenaline
65 β-endorphin
65 Cortisol
65 Vasopressin
Questionnaires 595 VAS
287 MDS
123 Comparative
Treatment 19 Gold implants x
19 Sham treatment x
II (2) n=61+7 Clinical examinations 254 Rectal temperature
IV (2) n=45+6  254 Palpation
V (2) n=44+7 254 Lameness exam
254 Jumping onto table
254 Climbing stairs
254 Hip function (ROM)
254 Orthopaedic examination
254 Neurological examination
Force plate study 254 10-80 runs per dog/time
Radiology 68 Official hip/elbow radiograph x
14 Others, when needed x
Serum samples 254 BUN 
254 Creatinine
254 ALAT
254 AFOS
254 Total protein
254 albumin
Questionnaires 508 VAS
254 MDS
In trial 1, all dogs were examined at the hospital on four different occasions. 
At the first visit (W0), the patients were initially evaluated (I, III) and then 
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treated (III). Follow-up visits for reassessments were at 4, 12, and 24 weeks 
posttreatment (W4, W12, and W24) (III). The hip area was clipped (depending 
on dog size 15 x 15 cm to 30 x 30 cm) and given a surgical scrub. All points 
found with the Ohm-meter (usually three) were implanted with one gold 
bead per site through hypodermic needles of different lengths and with a 
diameter of 14 G (∅ 1.2 mm). A stiletto was used to hold the gold down 
in the tissue, as the hypodermic needle was retrieved. The control group 
was treated similarly, but no implants were inserted. Instead, they just had 
three “needle holes” made through the skin, using the same size needles, 
but with no gold and at locations that were not acupuncture points. For 
details of treatment, see study III. All dogs were sent home with the same 
instructions for rest and exercise. 
In trial 2, the location of the disease (hip or elbow OA) was the only 
thing that was stratified for in the randomization (IV,V). The dogs were 
given the GLM (IV), the HCP (V) and the positive and negative control 
treatments (IV,V) orally for 8 weeks, from W0 to W8 (for treatment regime, 
see Table 4). Two control groups were included: the established positive 
control carprofen and a negative control, i.e. the dog received all three 
products as placebos. Follow-up visits with questionnaires for reassessment 
were at 4, 8, and 12 weeks (W4, W8, and W12). At W12, the dogs had been 
off all medication for 4 weeks and were evaluated to determine long-term 
effects of the different treatments. 
For a time flow chart for trial 2, see Table 5, and for exact dosing, see 
studies IV and V.
Table 4. Treatment groups and medication regime used in trial 2.
Treatment groups and medication (n= number of patients per group, GLM = green 
lipped mussel, HCP = homeopathic combination preparation).
Group (n) Three products / dog, taken daily for eight weeks Study
GLM (15) Real GLM HCP placebo carprofen placebo IV
Carprofen (15) GLM placebo HCP placebo Real carprofen IV,V
Placebo (15) GLM placebo HCP placebo carprofen placebo IV,V
HCP (14) GLM placebo Real HCP carprofen placebo V
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Table 5. Time flow chart for trial 2.
W-4 - W12. W refers to week and the subscript to the number of the week before (-) or 
after the start of medication. 
Time Study Procedure
W-4 II Baseline 1, for pain assessment trial (test)
  Any analgesic/chondroprotective medication withdrawn
 IV-V Baseline for analgesic used
  Questionnares for owners (training)
W0 II Baseline 2, for pain assessment trial (retest)
  Baseline for all other variables, force plate, veterinary evaluation
  Clinical, neurological, and orthopedic examination
 IV-V Radiographic examination
  Blood samples
  Start of medication perorally
  Questionnaires for owners
W4 II Treatment evaluation after 4 weeks for pain assessment trial
  Midpoint evaluation (4 weeks), force plate, veterinary evaluation
 IV-V Blood samples
  Questionnaires for owners
W8 II Treatment evaluation after 8 weeks for pain assessment trial
  Endpoint evaluation (8 weeks), force plate, veterinary evaluation
 IV-V Blood samples
  Questionnaires for owners
W12 II Back to baseline for pain assessment trial
  Follow-up evaluation (8 weeks), force plate, veterinary evaluation
 IV-V Blood samples
  Questionnaires for owners
assessment of chronic pain and other clinical trial 4.3 
outcome measures
owner evaluations: mds questionnaire and vAs scales4.3.1 
The gathering of the “right questions” for a scale is a long pre-trial process 
and in the case of our study, started a year before the final first questionnaire. 
Face and content validity was tested as the items for the first questions were 
gathered from own clinical experience, previous research and literature, 
and from informal interviews with owners and colleagues. We finally 
ended up with 25 MDS questions that were tested several times until all 
ambiguous or poorly worded questions had been deleted or rewritten and 
again retested. 
In our trials, the basic questionnaires consisted of different parts (I-V). 
The first part was an MDS questionnaire containing 25 (I,III) or 18 (II,IV,V) 
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questions about mood, behavior and locomotion of the dog; owners 
answered using a descriptive scale of 0-4 (I-V). Detailed descriptions of 
the questionnaires can be found in studies I and II and in Appendix 2. 
Responses 0-1 were considered typical for a healthy dog and responses 2-4 
typical for a dog with chronic pain (II, IV, V). 
The second part of the questionnaire consisted of two plain-line 10-cm 
visual analog scales (VAS): one for pain and the other for locomotion. The 
end of the line to the left signified no pain, or no difficulties in locomotion, 
whereas the right end signified the worst possible pain, or the most severe 
difficulties in locomotion (I-V). 
In trial 1 (I,III), the MDS questionnaire and the VASs were answered 
seven times: at W0 as baseline before the treatment (I,III), at W1, W2, W3 
at home, and at follow-up W4, W12, and W24 (III). The questionnaire was 
entitled “Pain questionnaire for dogs with CHD”, and the first one (W0) 
was completed by the owners and veterinarians together at the hospital, 
and the rest of them were completed at home. From the third visit onwards 
(at W12 and W24), the owners also answered a comparative questionnaire, 
aimed at assessing changes in the dogs’ performance and status with respect 
to locomotion, climbing stairs, and signs of pain after 12 and 24 weeks. 
Here the owners had to choose from the following: “has improved”, “has 
remained unchanged”, or “has deteriorated” (III). 
In trial 2 (II,IV,V), the MDS questionnaire and the VASs were answered 
five times: W-4 (II), W0, W4, W8, and W12 (II,IV,V). The first one was sent 
home to the owners 4 weeks before the trial started (W-4) with no additional 
guidance as to what the different variables represented. There was no 
heading including the words “pain” or “assessment” on the questionnaire 
to avoid respondent bias (Vaillancourt 1991), the heading was simply “The 
general status of the dog now”. No instructions, no key to the questions, and 
no helpful comments were included. The owners were told that the same 
person would have to fill in the questionnaire every time, and to confirm 
this they were asked to sign each questionnaire after completing it (II). 
The second questionnaire was also a pre-treatment baseline questionnaire, 
completed just before the first visit (W0), before the treatments or placebos 
were administered (II,IV,V). Both baseline questionnaires were answered 
during the dry cold winter season. The three other questionnaires were 
given to the owners at the clinic, to be taken home and completed there, 
again without help or guidance (IV,V). Here, four questions about possible 
adverse reactions to treatment had been added, including changes in 
appetite, vomiting, diarrhea and atopic skin reactions. The third and fourth 
questionnaires (W4 and W8) were answered after having given the dogs the 
analgesic or a placebo for 4 or 8 weeks, and the last questionnaire (W12) 
was a follow-up, answered 4 weeks after having discontinued all treatments 
(IV,V). The MDS questionnaire was used both for psychometric testing (II) 
and to evaluate a treatments (IV,V).
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The owner questionnaires were answered by owners or someone living 
in the same household as the dog. They had never participated in this kind 
of evaluation before. The questionnaires were written in Finnish language. 
In Trial 1 (I,III) the gold implant treatment was performed in March and in 
trial 2 (II,IV,V) the actual treatment period was from February to April. 
mobility evaluations by veterinarians4.3.2 
Lameness (from walk, trot, and gallop), jumping onto a small table, and 
climbing stairs were evaluated by two veterinarians (I,III-V). The evaluation 
form had a simple descriptive scale with 5-point grading, different for all 
three scores (Table 6). The three scores of both veterinarians were summed, 
allowing a minimum score of 0 and a maximum of 24 (2x3x4). This variable 
was first named “locomotion” (I,III), but in the second trial the name was 
changed to “veterinary-assessed mobility index” (IV,V). The latter name 
will now be used throughout the thesis. 
In trial 1 (I,III), two veterinarians independently evaluated lameness, 
jumping, and climbing stairs as well as the clinical examination, including 
ROM testing from videotapes taken at four different times, W0, W4, W12, 
and W24. The dogs were coded by number and the videos were shown in 
random sequence to the evaluators. The veterinarians did not evaluate the 
control dogs used in the pain assessment study (I).
In trial 2 (II,IV,V), two veterinarians independently assessed mobility, 
as in trial 1, but in real time, i.e. no videos were used. For more details, see 
studies IV-V.
plasma hormone assays4.3.3 
In trial 1, concentrations of the catecholamines adrenaline and 
noradrenaline, β-endorphin, cortisol, and vasopressin were measured. 
Plasma was collected from all dogs in the clinical study and from the 23 
healthy blood sample control dogs (I). 
In trial 2, blood samples were collected from all dogs at each visit and 
blood urea nitrogen (BUN), creatinine, serum alanine aminotransferase 
(ALAT), alkaline phosphatase (AFOS), total protein, and albumin were 
analyzed (IV,V).
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Table 6. Descriptors for veterinary assessment grades.
  Lameness:            0.    Totally normal, no lameness
Slightly stiff, not so keen to move, minor 1. 
lameness
Clearly stiff, clearly does not move 2. 
freely, pacing, slightly lame
Clear lameness3. 
Totally lame, avoids weight-bearing on 4. 
affected limb
 
   Jumping:             0.    Jumps normally, well
A slightly careful jump1. 
Jumps with a bit of difficulty, climbs up2. 
Jumps or climbs with great difficultly3. 
Will not even try because of difficulty/4. 
pain
   Stairs:                0.    Walks stairs normally
Slightly careful, uses both paws 1. 
successively, not so keen to move
Sometimes uses both paws at the same 2. 
time, clearly does not move freely
Bunny-hops all the time, walks stairs 3. 
with great difficulty
Will not even try because of difficulty/4. 
pain
radiographic examination 4.3.4 
Radiographs were taken, at baseline (I-V) and at W24 (III), of the 
coxofemoral joint (I-V) and/or elbow joints (IV,V), and other joints if 
considered relevant.
In trial 1 (I,III) dogs were sedated and positioned in ventrodorsal 
recumbency with limbs fully extended and the stifle joints internally 
rotated. An official veterinarian from the Finnish Kennel Club performed 
masked evaluations of all radiographs. Coxofemoral joints were evaluated 
for osteoarthritic changes. The degree of abnormality in a coxofemoral 
joint was assessed from 13 radiographic features using 2- to 5-point scales, 
and these were combined to form 9 variables (see Table 7 and Study I for 
details). Control dogs were not radiographed.
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Table 7. Factors evaluated from the ventrodorsal radiographs of the coxofemoral joint 
of dogs with CHD (I).
Radiological changes Evaluated as
Norberg angle >105° / 90°-105° / 75°-90° / 60°-75° / 45°-60°
Changes of femoral neck:
     -Length of femoral neck normal / short
     -Femoral neck no exostosis / some / a lot
Area of physeal scar no changes / some / a lot
Femoral head shape normal / slightly flattened / very flattened / grossly deformed
Changes of acetabular rims:
     -Dorsal acetabular rim no exostosis / some / a lot
     -Cranial acetabular rim no exostosis / some / a lot
     -Caudal acetabular rim no exostosis / some / a lot
Acetabular cavity deep / shallow / non existent
Incongruence of joint space no incongruence / some / total
Acetabular fossa normal / slightly filled / totally filled
Exostosis in joint - anywhere no exostosis / some / a lot
Bone chip in joint - anywhere no chip / one / many
In trial 2 (IV,V), all dogs were sedated and a ventrodorsal radiographic 
picture of the coxofemoral and/or a lateral elbow picture was taken, only 
to confirm diagnosis. 
Force plate analysis4.3.5 
In trial 2 (IV,V), gait was assessed by force plate analysis (Kistler force plate 
type 9286AA, Kistler Instrumente AG Winterhur, CH-8408, Switzerland), 
which objectively evaluates weight-bearing of limbs. The signal from the 
plate is processed and stored using a computer-based software program, 
and velocities and acceleration are determined by three photoelectric cells 
placed 1 m apart and a start-interrupt timer system (Aquire 6.0, Sharon 
Software Inc., DeWitt, MI, USA). The dogs were trotted from left to right 
by their owners. The speed had to be in the same range (± 0.5 m/s) for 
the dog each time the test was performed (at W0, W4, W8, and W12). The 
acceleration was <0.5 m/s/s, and contact had to be made with the plate first 
by the forelimb and shortly thereafter by the hind limb of the same side 
for the evaluation to be valid. The test was repeated until sufficient valid 
results were obtained for both left and right limbs. A minimum of three 
valid measurements for each side and for each visit were then chosen by a 
blinded assistant, who did not otherwise participate in the study, according 
to speed, acceleration, and no interferences, such as gait abnormalities or 
extra body movements. The mean of these three measurements was used 
for analysis. The ground reaction forces were normalized for the body 
weight of each dog, and mean peak vertical force (PVF) and mean vertical 
impulse were used as variables. Only measurements from the most severely 
affected limb at time W0 were used in the analysis. 
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Statistical analyses4.4 
The number of dogs required in each group in the clinical studies (III-V) 
was calculated for a two-tailed test (Fisher). The sample size was designed 
to be sufficiently large to detect a preset difference in treatment outcome 
(effective vs. not effective, based on previous human or canine studies, 
when available) with a statistical power of 0.8 and allowing for a 5% alpha 
error. In all studies, all tests were two-tailed and a P-value of < 0.05 was 
considered significant. All statistical tests were preformed using SPSS 12.0 
for Windows (SPSS Inc., Chicago, IL, USA).
Study I: Possible bias in the two control groups and in the group of dogs with 
CHD was assessed with a t-test and cross tabulation. Data obtained from 
the questionnaires were compared with VAS scores, with veterinarians’ 
lameness scores, and with the radiographic changes by means of Spearman 
rank correlation test. Because of the uneven distribution of the data, a 
Mann-Whitney test was used to compare the questionnaire answers given 
by the owners of control dogs with those given by owners of dogs with 
CHD, and to compare plasma hormone concentrations in control and OA-
affected dogs. 
Study II: See Appendix 2. Construct validity was studied using principal 
component analysis (PCA) with varimax rotation. Only components (PC) 
with an eigenvalue exceeding one were interpreted (Tabachnick & Fidell 
2007); in this, loadings exceeding 0.4 were emphasized (Streiner & Norman 
1995). A Keiser-Mayer-Olin Measure (Kaiser 1960) of sampling adequacy 
that is over 0.6 shows that the data is suitable for component analysis.
Reliability of the index was assessed by two methods: 1) Cronbach’s-α 
at W0 was used to check for internal consistency or the degree of mean 
correlation among the eleven items of the index and among items of the 
components extracted. 2) The test-retest reliability model was used where 
the mean values of the index and the eleven individual items (questions) 
of the questionnaire were compared at two baseline measurements (at W-4 
and W0), using intra-class correlation and the Spearman correlation tests. 
Similarity of Cronbach-α at the two baseline evaluations would support a 
stable correlation structure. A high intra-class correlation and similarity of 
the mean values would indicate repeatability. Sensitivity to change of the 
index was studied using the independent samples t-test to compare the 
mean index score (and separate question) values between the medicated 
and placebo groups at all time points and especially during medication, i.e. 
at W4 and W8. Provided that to the two groups do not differ before (W-4 
and W0) medication, smaller scores (meaning less pain) in the medicated 
group during medication would indicate the index’s sensitivity to change. 
Baseline bias between the treated and placebo group was assessed with a 
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chi square test and cross tabulation. At W-4, W0 and W12, neither of the 
groups were medicated; they are thus expected not to differ with respect to 
the index score and even individual item means. Testing of this expectation 
calls for similarity testing (Schuirmann 1987) that fundamentally differs 
from the ordinary use of the standard t-test. In its strictest sense, similarity 
testing requires a pre-statement of a similarity limit (Schuirmann 1987). 
Because the maximal clinically tolerated difference in evaluated pain is 
not known, we relied on the PDS (potentially data supported) approach of 
Rita and Ekholm (2007): it gives the largest difference of the index score 
(and item) means that is statistically consistent (at e.g. 0.05 risk level) with 
the observations. Hence, if the obtained PDS-difference can be regarded 
as clinically small, we gain statistical support to the similarity of the 
index score and item means of the two groups at the time points when 
their medication is the same. The same PDS-approach was also applied 
to argue for similarity of correlations and differences of the two baseline 
measurements at W-4 and W0.
Study III: Bias for major background variables between the two groups was 
calculated using Chi-square tests. The Sign test was used to evaluate the 
improvement in locomotion seen by the veterinarians. There, if the grades 
for the five variables concerning mobility had either all improved or some 
improved and some stayed unaltered, the mobility index was considered 
to have “improved”. If the variables had either all deteriorated or some 
deteriorated and some stayed unaltered, then the mobility index was 
considered to have “deteriorated”. If there was no change in any variable or 
if there were both changes for the better and changes for the worse, they 
were “unchanged”. 
The Spearman correlation test was used to test the assessments of the 
two veterinarians. Analysis of variance for repeated measures, with time as 
a within-factor and treatment group as a between-factor, was used to study 
the temporal patterns of the owner reported VAS data. 
Studies IV and V: For calculating the percentage of dogs per group that 
improved between baseline and W8, the results of each variable were 
converted into dichotomous responses of “improved” and “not improved”. 
Dogs that deteriorated, that used rescue carprofen more than three times 
per week at W8, and dogs with no change in the evaluated variable were 
considered “not improved”. Differences between the treatment groups and 
the two control groups were calculated using a Chi-square test. The odds 
ratio was calculated using the common Mantel Haenszel odds ratio estimate, 
and the confidence interval (CI) was set to 95%. An odds ratio (including 
CI) over 1.0 indicated a beneficial effect of the tested treatments. 
The change from baseline to W8 was also calculated as a mean and 
median for each variable. For dogs that had used extra carprofen more 
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than three times per week at W8, the variable values at evaluation W8 were 
changed into the most negative value measured at that time, separately for 
each variable. This was done to counteract the effect of the extra NSAID 
taken and enabled us to use the whole data in the statistical analyses. The 
difference between the two tested treatments and the two control groups 
group were analyzed using the Mann-Whitney U-test. The change from W0 
to W8 in the force plate variables was similar for the front and hind limbs, 
although the values were different. Therefore, force plate data collected 
from all four limbs were analyzed together. 
Dogs for which we did not manage to get force plate results due to major 
lameness were considered “not improved” in the dichotomous analyses, 
but were excluded from the median change data. A Pearson correlation 
test was used to evaluate the association between the assessments of the 
two veterinarians.
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RESULTS5. 
All evaluations of outcome and pain assessing variables were done during 
trial 1 (I). Further validation of a MDS questionnaire was done during trial 
2 (II). Some of the variables were used as outcome measures in the clinical 
studies (III-V).
As no statistically significant bias existed between the groups at baseline 
in any of the trials, no adjustments were necessary.
pain/outcome assessing studies (i-ii): 5.1 
owner evaluations (i,ii)5.1.1 
MDS questionnaire and the Helsinki chronic pain index (HCPI) 5.1.1.1 
(I,II)
Validity (I) – In trial 1 (I) comparison of the questionnaire answers 
provided by owners of dogs with CHD with those provided by owners of 
control dogs with no pain revealed significant differences (P<0.001) in 
answers to 17 of the 25 questions (Table 1 [I]). Eleven of these 17 were 
selected, as “bad” items that either were not applicable to all owners (e.g. 
stair climbing), that were not easily understood (e.g. pacing) or that did 
not show a significant difference between healthy and diseased dogs (e.g. 
appetite), were dropped at this stage, resulting in the eleven item Helsinki 
chronic pain index (HCPI) (see Appendix 2). The index number was derived 
from the 5 possible answers (scores of 0-4); for the 11 questions selected, 
there was a possible minimum index number of 0 (11 x 0) and a possible 
maximum index number of 44 (11 x 4). There was a significant difference 
in the HCPI between the CHD dogs and the used control dogs of our first 
study; index range 7-35 and median 19 compared to range 0-5 and median 
2, respectively (Table 1 [I]). The dogs that were given rescue analgesics 
were scored as having shown significantly more pain (veterinarians 
P=0.006, owners P=0.016) than the dogs not given meloxicam, already 
indicating that the first questionnaire was sensitive. The HCPI correlated 
significantly with the pain and locomotion VAS scores for dogs with CHD 
(R=0.65, P<0.001 and R=0.65, P<0.001 ) (Table 2 [I]).
In trial 2 (II), the cohort of 61 dogs with OA had a chronic pain index 
of 4-28 (median 17). The Kaiser-Mayer-Olin Measure (Kaiser 1960) of 
sampling adequacy was equal to 0.78, showing that the data is suitable for 
component analysis. Communality values tended to be moderate to good 
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(0.30-0.86). The unrotated PCA component matrix at W-4 and W0 extracted 
three components with an eigenvalue >1, but the scree plot suggested only 
one component (PC) should be accepted (Figure 1 [II]). The accepted first 
component’s 10/11 items had very similar loadings at W-4 and W0, (0.44 to 
0.68 and 0.44 to 0.76, respectively), vocalization being the only item with 
a loading of only 0.20 and 0.27, respectively (see Figure 2 [II]). There was 
a high correlation at W0 between the PC(W0) and the HCPI value, r=0.99. 
The mutual correlation of PC(W-4) and PC(W0) was high (0.91) (Fig. 5). 
Fig. 5. Scatterplot of the mutual correlation of PCs (all 11 items) at W-4 and W0 
(R=0.91)
When further evaluating construct validity, a varimax rotation at W-4 
extracted three components with an eigenvalue over one that we were not 
able to interpret while the rotation at W0 extracted three components that 
could easily be clinically interpreted. These three components (PC1,-2,-3) 
at W0 explained 59.1 % of the total variation among the eleven index items. 
In the first PC1(W0) there were eight items (questions 4 to 11) with higher 
component loading (0.50-0.80) and as they were all related to mobility, 
we called this component “mobility”. The second component PC2(W0) 
had two items related to “mood” (questions 1 and 2) with component 
loadings of 0.78-0.92. The third component PC3(W0) had one single item, 
“vocalization” (question 3) with a loading of 0.88 (to see the items, see 
Appendix 2).
Internal consistency (II) – The Cronbach’s-α of the eleven questions at time 
W0 was 0.82, with an inter-item correlation mean of 0.31, indicating internal 
consistency through an acceptable level of mean correlation among the 
pc(W-4) versus pc(W0)
pc
(W
-4
)
pc(W0)
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questions in the questionnaire. If single items were deleted, the Cronbach-α 
values still ranged from 0.79 to 0.83. The fact that the reliability coefficients 
of the index here remain high, emphasize the internal consistency reliability 
of the index. If the index was looked at as having three components, the 
Cronbach’s α of the two first components at time W0 were PC1(W0) =0.81 and 
PC2(W0)=0.80, whereas PC3(W0) could not be calculated since the 
component included only one item.
Repeatability (II) –The 11 items (and the total HCPI score) had an intra-
class correlation of 0.90 when tested at the two baseline evaluations four 
weeks apart (at W-4 and W0), indicating a high test-retest reliability. The 
Pearson rank correlation between the HCPI index scores measured at the 
two baselines, four weeks apart (at W-4 and W0), was 0.92 (P<0.001) and 
between two same items the Spearman correlation coefficients ranged 
from 0.62 to 0.88. The PDS was calculated to ensure reliable results, despite 
small sample size. The smallest PDS correlation (Rita & Ekholm 2007) that 
was consistent with the HCPI score was 0.82 (Table 1 [II]).
At the two baselines, the mean HCPI total scores were similar: the 
observed mean HCPI total score decrease from W-4 to W0 was only 0.278, 
which is less than 2% of the mean index value at W-4 (16.00). Calculated 
using PDS, the largest consistent population change (0.752) would be 
around 4.7%. The individual items naturally showed more variation. The 
largest PDS calculated consistent population change would be, however, 
10% at most. 
Sensitivity to change (II) –There was no significant baseline bias in HCPI 
total score, rescue medication, gender, age, bodyweight or time having 
suffered from OA symptoms, between the two treatment groups. The HCPI 
total score means in the placebo and medicated group were similar at W-4 
and W0, their differences (1.87 and 0.79, respectively; Table 2 [II]) being 
11 and 5% of the corresponding index mean in the placebo group (17.20 
and 16.64). 
During medication, the index mean in the placebo group exceeded that 
of the medicated group by more than 60% at W4 and by 123% at W8 (HCPI 
of medicated group during W4 and W8 were 9.62 and 7.69, respectively) 
(Table 2 [II]), indicating that the index is sensitive. 
VAS scales (I)5.1.1.2 
In trial 1 (I) the pain and locomotion VAS scores for dogs with CHD 
correlated significantly with each other (R=0.71, P<0.001). Neither of them 
correlated with the veterinarians’ combined locomotion score (R=0.06, 
P=0.72 and R=0.17, P=0.29, respectively).
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veterinary-assessed mobility index / locomotion5.1.2  (i)
In trial 1 (I) the locomotion evaluations provided by the two veterinarians 
were in agreement (lameness, R=0.60, P≤0.001; ability to jump on and 
off a table, R=0.78, P<0.001; and ability to climb and descend stairs, 
R=0.63, P≤0.001). Some correlation between the calculated HCPI and the 
veterinarians’ combined score was detected (R=0.35, P=0.047), but there 
was poor correlation between most of the answers to individual questions 
(Table 2 [I]). 
plasma hormone assays (i)5.1.3 
A significant increase in adrenaline, cortisol, and vasopressin and a 
significant decrease in β-endorphin concentrations was seen between 
the controls and the dogs with CHD (Table 3 [I]). There was considerable 
individual variation in all of the measured plasma hormone concentrations. 
Adrenaline concentration had a significant positive correlation with 
noradrenaline and cortisol concentrations. Neither of the two VAS scores 
nor the veterinarians’ combined score correlated with plasma hormone 
concentrations in dogs with CHD.
radiographic examination (i)5.1.4 
A significant correlation was found between the Norberg angle and change 
within the area of the physeal scar (R=0.52, P=0.001), shape of the femoral 
head (R=0.44, P=0.009), exostosis of the acetabular rims (R=0.35, P=0.034), 
the acetabulum (R=0.72, P<0.001), and appearance in the acetabular fossa 
(R=0.65, P<0.001). Of the radiographic variables, none correlated with the 
veterinarians’ combined mobility score or with the owners’ pain VAS score. 
Variables that correlated with the owners’ locomotion VAS score were 
exostosis in any region of the joint (R=0.34, P=0.04) and number of bone 
chips in any region of the joint (R=0.34, P=0.034). No correlation existed 
between duration of clinical signs of CHD and severity of radiographic 
abnormalities.
experimental treatment studies (iii-V):5.2 
Gold implant study (iii)5.2.1 
Owner evaluations (III)5.2.1.1 
The VAS data submitted by the owners showed overall a highly significant 
improvement in the treatment group in locomotion and a highly significant 
decrease in pain (P=0.0001 and P=0.0034) during the trial period (for 
locomotion, see Fig. 4 [III]). These differences were not statistically 
significant between the two treatment groups (P=0.41 and P=0.24, 
respectively). When changing outcome to “improved”, “unchanged”, or 
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“deteriorated”, 53% of treated dogs and 63% of control dogs were evaluated 
as improved, but the differences between the treated and control groups 
were not statistically significant (P=0.80) (Fig. 3 [III]).
When the blinded owners were asked to evaluate the success of treatment 
at the end of the study, no significant difference emerged between the two 
treatment groups (P=0.895). In the comparative questionnaire, there were 
no statistically significant differences in tested variables between groups at 
either W12 or W24. 
Veterinary-assessed mobility index/locomotion (III)5.2.1.2 
When comparing W24 with W0, a significant improvement was found in 
the veterinary-assessed mobility index for the treated group (P=0.036). 
However, the mobility index showed no statistically significant difference 
between the two groups (P=0.19). According to the blinded veterinarians, 
65% of treated dogs and 53% of control dogs had improved locomotion 
(Fig. 2 [III]). When comparing the two veterinarians’ assessments of 
hip function, there was a very low negative, non-significant correlation 
(R=-0.15), so these results were not reported. 
Radiographic examination (III)5.2.1.3 
No migration of implants was detected in radiographs of the coxofemoral 
joint taken at W24, six months after implantation.
Complications and side-effects (III)5.2.1.4 
No side-effects were reported. Two dogs from the placebo group were 
euthanized between weeks 12 and 24 because of signs of intense pain due 
to OA.
GLm and Hcp studies (iv,v)5.2.2 
Baseline values for individual groups in studies IV and V can be seen 
in Table 8. No statistically significant bias existed between the groups at 
baseline in any of the trials.
Eight of the 68 dogs were excluded from the material at some time 
during the study because they no longer met the medical inclusion criteria 
(operation on the affected hip joint (n=1), transverse vertebra diagnosed 
after inclusion (n=2), cruciate ligament injury (n=2), degenerative 
myelopathy (n=1), polyarthritis of the phalanges (n=1), and castration 
just prior to the third visit (n=1)). There were 4 dogs, all from the placebo 
group, that had used extra carprofen more than 3 times per week at W8, 
and two dogs from the placebo group and one from the GLM group were 
unable to trot over the force plate (see Statistical Analyses, p. 54). The odds 
ratios for all variables are given in studies IV and V.
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Table 8. Distribution of possible confounding factors between groups at time W0 (for 
extra NSAIDs at W-4) (GLM = green lipped mussel, HCP = homeopathic combination 
preparation, NSAID = nonsteroidal anti-inflammatory drug, OA = osteoarthritis, SD= 
standard deviation, PVF = peak vertical force, VAS = visual analog scale) (IV,V).
Possible confounding
factors
Carprofen GLM HCP Placebo
n 15 15 14 15
n with hip dysplasia 12 12 12 12
n with elbow OA 3 3 2 3
Sex: Male/Female 7/8 8/7 8/7 10/5
Median age (years);            
Min – Max
5                   
1 - 9
7                   
2 - 10
7.5                
1 - 11
6                   
1 - 11
Median duration of signs 
(years) > 2 1-2 1-2 1-2
Median weight (kg);           
Min – Max
38                
31 - 56
34                
20 - 49
27.5            
22 - 54
34               
18 - 54
Mean ± SD of continuous 
variables at start of trial
Veterinary-assessed mobility 
index 5.00 ± 4.61 6.07 ± 4.51 6.79 ± 6.46 5.20 ± 4.26
Force plate-PVF 75.92 ± 23.48
77.41 ± 
16.69
70.96 ± 
22.58
78.46 ± 
22.23
Force plate-impulse 10.92 ± 4.02 10.07 ± 3.04 8.64 ± 3.06 9.72 ± 3.43
Owner-assessed Chronic pain 
index 16.47 ± 6.21 14.60 ± 4.76 15.86 ± 6.20 14.87 ± 4.79
Owner-assessed pain VAS 
(cm) 3.55 ± 2.17 3.87 ± 1.82 4.24 ± 2.16 3.70 ± 1.77
Owner-assessed locomotion 
VAS (cm) 4.57 ± 2.03 4.36 ± 2.03 4.87 ± 2.26 4.61 ± 2.12
Median, Min - Max of vari-
able at 4 weeks prior to trial 
(W-4)
NSAID doses per month
none, none -
3-5/week
none, none –
about 1/
week
none, none – 
daily/
almost daily 
none, none –
about 1/
week
Owner evaluations (IV,V)5.2.2.1 
When the data of all variables had been converted to the dichotomous 
responses of either “improved” or “not improved”, there were significantly 
more improved dogs in the GLM group than in the placebo group according 
to two of the three owner-assessed variables; HCPI (P=0.028) and pain 
VAS (P=0.011). Locomotion VAS was not significant, but showed a similar 
trend (P=0.070) (Table 9). 
Using the same dichotomous responses for the HCP study (V), only 
the pain VAS (P=0.043) of the three owner-assessed variables indicated 
significantly more improved dogs in the HCP group than in the placebo 
group (Table 9). 
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A highly significant difference was present in the extent of improvement 
between the GLM and placebo groups in the pain VAS (P=0.004), and a 
second variable was close to being significant; locomotion VAS (P=0.057). 
The difference in the extent of improvement between the HCP and the 
placebo was significant according to the chronic pain index (P=0.049) and 
the pain VAS (P=0.020) (Table 9).
Veterinary-assessed mobility index (IV,V)5.2.2.2 
When the data of all variables were converted to the dichotomous responses 
of either “improved” or “not improved”, according to the veterinary-
assessed mobility index there were significantly more improved dogs in 
both the GLM group (P=0.031) (IV) and the HCP group (P=0.018) (V) 
than in the placebo group (Table 9).
There was also a significant difference in the extent of improvement in 
the veterinary-assessed mobility index between both GLM (P=0.012) and 
HCP (P=0.015) groups and the placebo group (Table 9). The evaluations 
of the two veterinarians correlated well (R=0.853, P<0.01) in both studies 
(IV,V). 
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Force plate analysis (IV,V)8.3.6.1 
None of the force plate variables indicated significant differences 
between the GLM product and the placebo (Table 9). 
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In the HCP study, when the data of all variables were transformed into 
dichotomous responses of either “improved” or “not improved”, the PVF was 
significantly better in the HCP group (P=0.006) than in the placebo group. 
A significant difference was also present in the extent of improvement in 
the PVF (P=0.028) between the HCP group and the placebo group (Table 
9).
Intake of rescue NSAIDs (IV,V)5.2.2.3 
At W-4, before the owners were told to stop all medication, 14% of dogs 
in the carprofen group, 13% in the GLM group, 28% in the HCP group, 
and 8% in the placebo group were given rescue NSAIDs once a week or 
more. At W8, 0%, 7%, 14%, and 27% of the respective groups were given 
additional carprofen once a week or more (Fig. 6). At follow-up (W12), 
the respective numbers were 33%, 14%, 21%, and 29%. In the GLM study 
(IV), the differences between both GLM and carprofen compared with 
the placebo group at time W8 were significant (P=0.021 and P=0.008, 
respectively), but in the HCP study (V), only the difference between the 
carprofen group and the placebo group was significant (P=0.012) at W8. 
carprofen GLM HCP placebo
Group
0,0
0,2
0,4
0,6
0,8
1,0
%
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Extra carprofen      
at week 8
not at all
1-2 x / 4 weeks
once / week
3-5 x / week
daily/almost daily
Fig. 6. Proportion of dogs given extra rescue NSAIDs (Carprofen) at W8 in all 4 
treatment groups. Columns indicate the percentage of dogs per group that were 
administered extra carprofen during the 4 last weeks according to the following scale: 
1 = not at all, 2 = 1-2 times, 3 = about once a week, 4 = about 3-5 times a week, and         
5 = daily/ almost daily. 
Comparing the tested treatments to carprofen (IV,V)5.2.2.4 
When the data of all variables were converted to the dichotomous 
responses of either “improved” or “not improved”, none of the variables in 
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either study showed a statistical difference between tested product and the 
positive control group, given carprofen.
There was a significant difference in the extent of improvement only in 
the HCPI and in the locomotion VAS, but between both the GLM (P=0.004 
and P=0.005) and HCP (P=0.007 and P=0.019) groups and the carprofen 
group, where carprofen was more effective.
Complications and side-effects (IV,V)5.2.2.5 
In the study populations, all of the altered blood values and the clinical 
side-effects were considered mild or within normal range (IV,V). Two of 
the dogs for which no data were achieved on the force plate (one in the 
GLM group, one in the placebo group) were euthanized between W8 and 
W12 due to severe OA pain. 
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DISCUSSION6. 
Dogs6.1 
Dogs with CHD were selected as the target population since dogs with this 
disease form a typical group of patients suffering from chronic OA and 
due to that, pain. Also, they were considered to be readily available. The 
dogs used are representative of a normal population of canine OA patients; 
many dog breeds were included, but more of the breeds with higher 
incidence of CHD or ED were represented (statistics of the Finnish Kennel 
Club). The two trials were not totally comparable. The first trial comprised 
dogs suffering from CHD (I,III). However, as we had difficulty in getting 
enough dogs with CHD for the second trial, also dogs with OA due to ED 
were included (II, IV,V). To minimize bias, the dogs suffering from OA 
due to ED were stratified when allocated into groups. The problems with 
heterogenicity in the cohort will be discussed in the clinical trial section.
The placebo and carprofen have in previous studies shown 23-38% and 
56-81% of improvement in dogs with OA, as graded by veterinarians and 
owners (Holtsinger et al. 1992, Vasseur et al. 1995). As these numbers are 
similar to the results for these two groups in our second trial (26-40% and 
66-86%), our cohort appeared to reflect reality well. 
Variables chosen for outcome assessment6.2 
The results of our clinical trials highlight a problem with outcome 
assessment. In the second trial, we used 6-7 variables to assess treatment 
outcome. Depending on which of these are chosen as primary outcome 
measures, the results can vary markedly. According to force plate PVF, 
the homeopathic drug was very good, yielding 88% of the improvement 
produced by carprofen, while the placebo deteriorated 19%. The second 
force plate variable, vertical impulse, or locomotion VAS, indicated that 
GLM and HCP were of no use, with no significance being found for the 
two variables in either number of dogs improved per group or rate of 
improvement. According to the pain VAS, both treatments were effective, 
but no references to its validation as a valid outcome measure can be found 
in the literature. We have shown that the HCPI index is a good measure, but 
according to this outcome measure, only one of the two aspects is significant 
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for each of the two tested treatments. As seen, outcome assessment is not 
straightforward. Efforts should therefore continue to be directed toward 
finding valid and reliable chronic pain outcome measures to be used in 
research, as was done in our first two studies (I,II).
owner evaluations 6.2.1 
At the time of our first study, some articles had already been published 
on acute and postoperative pain evaluated by professionals such as 
veterinarians or technicians (Conzemius et al. 1997, Firth & Haldane 
1999). As there were no validating studies on canine chronic pain scales 
and because we needed chronic pain outcome measures to evaluate our 
treatments in the clinical trials, we decided to look into this. Innes and 
Barr (1998) where to our knowledge the first to publish an owner used 
VAS tool to assess outcome after an orthopeadic procedure for dogs. The 
reliability and responsiveness were estimated and found to be acceptable. 
As in our study, they found only few correlations between the different 
VAS scales and veterinarian assessment. Some years later Reid et al. (2000) 
published an abstract on the same topic and they continued their interest 
in this issue and have now developed a structured questionnaire on the 
basis of effects on health-related quality of life (Wiseman-Orr et al. 2004, 
2006). Their GUVQuest questionnaire is, however, very different from 
ours. Their questionnaire was developed from 109 chronic pain-describing 
items in 13 factors that were tested on 182 owners of dogs suffering from 
chronic pain. While our HCPI has 9 of 11 variables that have to do with 
mobility, of their 13 factors, only 1 comes from mobility. Our index may 
therefore be more appropriate for dogs suffering from chronic pain due to 
an orthopedic problem, while the GUVQuest might prove itself useful also 
for other causes of chronic pain. While our HCPI is now thoroughly tested 
(II), their scale is validated, but still awaits reliability testing.
A third questionnaire for use in assessing pain and lameness in dogs 
was later validated and tested for repeatability (Hudson et al. 2004). This 
scale started off with 39 questions that were presented as VAS scores, but 
none of them was an original pain VAS with endpoints from “no pain” to 
“most possible pain”. These authors ended up with 11 valid and reliable 
questions about locomotion, demeanor and mood (Hudson et al. 2004). 
They correlated the results of the questionnaire with a force plate evaluation. 
This would have been possible for us to do as well, but since our force plate 
measurements were so variable we opted not to. Of the 11 questions in 
Hudson et al. (2004), five to six are similar to the 11 questions in our HCPI 
(I,II) and seven of them deal with different aspects of mobility. As the HCPI 
and their VAS questionnaire are quite similar in content, but different in 
design, only time will show which of these two will be more used. 
Very recently a fourth chronic pain outcome measure has been 
introduced; the Canine Brief Pain Inventory (Brown et al. 2007). This 
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instrument has 10 items with a 11 point rating scale and one “Quality of 
life” question with a five point categoric response. Compared with our 
single factor scale, it has two factors: “severity of pain” and “interference 
with function”. This instrument was thoroughly tested and found to be 
valid and reliable.
Different researchers have used different ways of showing validity 
and reliability. For our index, reliability was shown with an intra-class 
correlation of 0.9, indicating a high test-retest reliability. A measure as 
small as 0.50 is considered sufficient for adequate temporal reliability for 
questionnaires (Cohen 1988, Streiner & Norman 1995). Reliability of the 
index structure in time can also be tested by comparing the Cronbach’s-α 
at two basically similar evaluations. As the rank correlations between the 
index values at the two baseline evaluations for our HCPI was high, this 
also indicates that the chronic pain index is reliable. For the same reason 
the individual questions per se can also be regarded as reliable (Table 1 
[II]). Our individual question correlations of r=0.62-0.88 were very similar 
to the correlations of Hudson et al. (2004), r=0.68-0.90. Brown et al. (2007), 
showed a high test-retest reliability with κ values of 0.75 and 0.81 for their 
two factors. Wiseman-Orr et al. (2006) have not yet tested their GUVQuest 
for repeatability.
Internal consistency was measured by component analysis, showing that 
at least 10 of the 11 questions were measuring the same thing and that the 
odd item (vocalization) was constant from time to time, but not a typical 
pain sign for all dogs. The individual components of the index gave rise to 
one or three interpretable principal components, but the one component 
model was more suitable according to psychometric testing (Kaiser 1960, 
Cattell 1978, Tabachnik & Fidell 2007). The one component model seemed 
to indicate a general level of pain, as the loadings of individual questions 
were very similar; except for vocalization. This is further supported by 
their high correlations with the index values. As the mutual correlation of 
the PCs at W-4 and W0 was high (Fig. 5, page 58) and the loadings at these 
times were very similar (Fig. 2 [II]), the index structure shows no trend 
in time, indicating internal consistency. A mean inter-item correlation 
>0.3 is considered good for an eleven item questionnaire (Nunnally 1978, 
Carmines & Zeller 1979).
Sensitivity to change (also called responsiveness) was shown as owners 
in the treatment group recognized a clearly better or more positive mood, 
behavior and locomotion of their dog when dogs were given daily analgesic 
medication compared with those that received no such medication. 
Previous studies have demonstrated the analgesic effect of carprofen in 
dogs with chronic pain (Holtsinger et al. 1992, Vasseur et al. 1995, Borer 
et al. 2003), and the results of our study support these conclusions. None 
of the other studies have yet tested their questionnaire for sensitivity to 
change.
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The HCPI has now been thoroughly tested and is considered suitable 
when dog owners should assess clinical outcome in a chronic pain trial. 
However, the HCPI has still only been evaluated for dogs with chronic pain 
due to OA and could also be evaluated for chronic pain due to other causes. 
As a change in language may have an impact on results, it should also be 
tested in English before one can be sure that the results of the psychometric 
tests are generally valid. It would also be interesting to determine cut-off 
points for severe, moderate, and mild pain in order to be able to better 
categorize pain for research purposes, but it is possible that it will not 
be possible with this index, since vocalization is a sign that not all dogs 
with chronic pain will show. It might prove difficult if one, based on the 
index, would try to distinguish dogs in pain from healthy dogs or try to 
find cut-off points to assess when analgesic medication should be given. In 
our first study (I) the items of our index were tested for construct validity 
by extreme groups (Streiner & Norman 1995), where dogs suffering from 
pain due to OA where compared to healthy dogs, having no pain. Only 
Brown et al. (2007) have validated their scale in a similar way. Neither of 
the other studies presented above mentioned mean or median values for 
the different questions, cut-off points or any of these other factors to be 
looked into (Wiseman-Orr et al. 2004, 2006, Hudson et al. 2004).
Potentially data supported results can be used to back up results from a 
smaller cohort. As many psychometric tests recommend the use of 100-300 
evaluators when testing a scale, our cohorts can be regarded as small. To 
compensate for this, we have paid special attention to the quantitative 
features in the analysis by also reporting the results as potentially data 
supported (PDS) values (Rita & Ekholm 2007). The PDS-approach enables 
estimation of the worst situation in a corresponding population (i.e. a 
population of similar dogs suffering from chronic pain due to OA) that is 
statistically consistent with the data. The approach gives us a value of the 
lowest possible significant correlation (at p<0.05) and the largest possible 
significant difference (at p<0.05) for a hypothetic larger, similar, cohort.
The strength of our HCPI index is that it is not too long to be 
overwhelming for the owner, nor too short to have a weak reliability. Made 
up of 11 separate questions, it has shown that it is capable of detecting a 
change in pain experience even in very small groups of dogs, although all 
questions per se do not show a significant difference between treated and 
non-treated dogs.
The pain and locomotion VASs are not discussed in this thesis as they 
require further attention and will be dealt with in two new articles later (in 
process). In a review concerning childrens pain it was concluded that the 
observational pain VAS had not yet been sufficiently tested, so that one 
could be sure of its adequate sensitivity (van Dijk et al. 2002). 
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mobility evaluation by veterinarians6.2.2 
In trial 1, a blinded veterinary evaluation from film material was used. 
Although lameness could easily be evaluated, the two veterinarians found it 
very difficult to evaluate hip function and pain from video tapes. Since this 
resulted in a poor correlation between evaluating veterinarians in Study III, 
indicating poor inter-rater reliability, it was not used in our second trial. 
The evaluated mobility had a good inter-rater reliability indicating that 
lameness evaluations can be done from videos. A surprising finding was 
that the veterinary mobility index did not correlate at all with the owner 
evaluated locomotion VAS although both should have been measuring the 
same thing.
In trial 2, we used two blinded veterinarians who assessed the dogs at 
the hospital (IV,V), which is one of the most commonly used outcome 
measures in clinical trials. It is striking that there seems to be no validated 
evaluations for veterinarian use. Although many different types of lameness 
scores, palpation scores, ROM scores, etc., have been used, none of these 
has, to our knowledge, been tested for validity or reliability. This was 
criticized in some recent articles (Schulz et al. 2006, Brown 2007, Kapatkin 
2007a), as rigorous evidence-based outcome evaluation is not possible if the 
outcome measures are not tested. Looking at the veterinarians’ combined 
mobility index in studies III-V, we can already identify some potential weak 
points. Of the combined score, 66% was related to jumping and traversing 
stairs, activities that dogs clinically may undertake with either excessive or 
minimal vigor in stressful situations. Some dogs will not jump or attempt 
stair-walking at the hospital, while other dogs jump, although they would 
never do so at home. Thus, a scale based on these activities might not be 
valid and/or reliable. We need a good, easy to use, valid and reliable gold 
standard veterinary used outcome measure for dogs with chronic pain. 
Then we could use this scale also to compare other scales with, but at the 
moment there is no such.
plasma hormone assays 6.2.3 
Our intention was to monitor plasma hormone concentrations in a 
realistic clinical setting, and therefore, we used the forelimb vein, the vena 
saphena. In many studies, blood samples are obtained via a pre-placed 
jugular catheter to minimize the effects of stress on the dog. Baseline 
hormone concentrations of the control dogs’ were compared with baseline 
concentrations in healthy dogs obtained from other studies (Hauptman 
et al. 2000, Väisänen et al. 2002) and were found to be similar, albeit 
not identical. Although there were significant differences in hormone 
concentrations between the groups with and without chronic pain, large 
individual variations made it impossible to define concentrations that 
would specifically indicate chronic pain. The stress of transporting dogs 
to the hospital may have had some influence on the results in our study, 
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as for example dogs that are new arrivals at an animal shelter are reported 
to have higher cortisol concentrations than those resident for a longer 
time (Hennessy et al. 1997). Thus, inclusion of physiologic measurements, 
such as plasma hormone concentrations, does not seem to provide much 
additional information regarding chronic pain in individual dogs.
radiographic examination 6.2.4 
Since exostosis and bone chips in any region of the coxofemoral joint were 
the only radiological findings associated with any of the measured chronic 
pain outcome variables, ie. with owner evaluated locomotion VAS, these 
are possibly associated with a physical restriction of movement because of 
the bony, advanced OA lesions in that joint. Since the appearance of the 
acetabular fossa correlated with most other variables in our study, it can 
be postulated that this may be one of the last radiographically detectable 
changes in the development of CHD. 
Our radiographs were taken with the legs fully extended in the traditional 
official hip position but in evaluating laxity of the hip joint, the Penn-Hip 
distraction index has proven to be more accurate (Smith 1997). However, 
none of these methods has been shown to detect dogs with clinical pain 
symptoms (Smith 1997). In no studies known to us, radiological findings 
of coxofemoral OA has, in fact, been correlated to clinical symptoms or 
chronic pain, it is just accepted as a clinical truth that they do not correlate. 
What we also found surprising was, that no correlation existed between 
the duration of the clinical signs of CHD and the severity of any of the 13 
evaluated radiographic changes. However, this lack of correlationis is also 
accepted as a clinical truth. Hence, the inclusion of radiographic data did 
not seem to provide much additional information regarding chronic pain 
in individual dogs. 
Force plate analysis6.2.5 
The force plate was not evaluated as a pain-assessing variable as it is generally 
perceived as the golden standard (Quinn et al. 2007), but it was used as 
a treatment outcome variable in the second clinical trial (IV,V). The limb 
measured to have the least PVF at W0 according to the force plate, was used 
in statistical analyses. The change from baseline to end of treatment in PVF 
and vertical impulse was in our studies within the same range as previously 
documented (see Table 9, given as medians); Budsberg et al (1999) recorded 
the change in PVF and vertical impulse from baseline to end of treatment 
as 1.6-2.3% and 0.13-0.22% of the dogs’ body weight, respectively, after an 
8-day analgesic treatment in dogs with OA of the hips. However, as our 
ranges for the medians (see Table 9) were quite variable and large, we did 
not find the method to be as valid and reliable as other researchers have 
done. Realizing how minor the changes are that indicate outcome, we can 
see that even small confounding factors may influence the results. 
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The following variables have been shown to introduce variability to force 
plate data: the dogs’ body weight as well as velocity and acceleration of the 
subject (Riggs et al. 1993, Roush & McLaughlin 1994), gait used (Voss et 
al. 2007), trial repetition (Budsberg et al. 1993, Jevens et al. 1996), interday 
testing (Rumph et al. 1999), limb symmetry (Budsberg et al. 1993), handler 
(Jevens et al. 1993), breed (Poy et al. 2000), selection and habituation of the 
subject (Rumph et al. 1997) and individual morphometrics (Budsberg et al. 
1987, Jevens et al. 1993). We tried to standardize velocity and acceleration, 
but used the owners as handlers, which amplified the variability. Another 
source for variability in our trial was due to size of the dog as we had many 
different breeds, body conformations, and body weights represented. We 
had to see that individual dogs kept the same speed thru the trial but the 
speeds varied some between dogs. This might have had an impact on group 
differences. Also, some dogs had to run tens of times before obtaining 
sufficient acceptable runs for both sides, giving very different values at the 
beginning and the end, when tired. Others have had similar problems, as it 
in a similar study was stated that each dog had to trot over the force plate 
a maximum of 75 times/session (Trumble et al. 2004). The non slippery 
rubber mat in our setting was probably not increasing variability as different 
surface (linoleum or carpet) has been investigated and did not have an 
impact on results (Kapatkin et al. 2007b). Our computer program initially 
accepted only whole kg body weight and as the value is a percentage of 
body weight and the change is marginal, this probably had some impact 
on our results as it led to at least a small change in body weight of the dogs 
between baseline and following evaluations. Our patient material was very 
heterogeneous, with dogs suffering from either CHD or ED, uni- or bilateral 
disease, minor or severe lameness. Some were so lame that no recordings 
were possible from the force plate. Thus, even when standardizing most of 
the potential confounding variables, the SDs were marked. 
In conclusion, after this, for us first study using a force plate, which yielded 
results indicating problems with confounding factors, our confidence in 
this method as the golden standard outcome measure is limited (IV,V). As 
it is difficult to standardize all influencing factors in clinical research trials, 
especially when using heterogeneous owner-owned different breed dogs, 
we feel that force plate evaluation should maybe not be considered the gold 
standard. Also Brown et al. (2007) pointed out that it relies on relatively 
strict inclusion criteria, which is a problem in clinical settings. However, 
with a more homogeneous group, more experience, more staff i.e. a handler 
that runs with all dogs, and more time per patient, this method may serve 
us better in the future. 
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Discussion on clinical research of oa6.3 
The three tested treatments will be discussed here in light of treatment 
outcome and possible mechanisms of action.
common problems in clinical research of oA 6.3.1 
Despite the small number of dogs per group and the large variation between 
individual animals, both the GLM and the HCP improved symptoms of 
OA significantly better than the placebo. However, the variation between 
individual dogs within groups was marked and thus increased the 
confidence intervals and subsequently may have reduced the significance 
between treatments. The factors due to force plate analyses were already 
discussed but many other factors may also have increased the variation. 
Firstly, it makes a big difference whether we are dealing with unilateral 
or bilateral disease and in our studies we allowed both. Dogs compensate 
differently depending on what leg/which legs are painful to use. In reality, 
it might even happen that when choosing the worst affected limb at the 
start of the trial, one might have chosen the “wrong” leg, as pain status 
does not correlate with radiographs, as 30-40% of dogs with OA suffer 
from multiple joint involvement (Olsewski et al. 1983) and as damage to 
one hind limb may lead to secondary lameness in an other leg as force 
is redistributed to the contralateral limb when the quadripeds muscles 
modify their compensatory loading over time (Budsberg 2001). If we have 
multiple legs involved, the compensation might tire other legs, showing up 
as lameness or subnormal force plate results for some other leg. All of these 
shifts can be seen as altered results and hence, even the stage of disease 
when a dog is taken into the study, is relevant. 
Secondly, OA is undulating, being better and worse at different times. In 
most articles covering the issue, weather is known to have an impact on OA; 
cold, damp and low barometric pressure will worsen OA pain symptoms 
(Guedj & Weinberger 1990, Aikman 1997, Strusberg et al. 2002, Verges 
et al. 2004, Liu et al. 2006), although there has also been some research 
that has not been able to show any correlation between weather and pain 
(Sibley 1985). Reversely, patients suffering from OA usually improve as 
the weather becomes warmer and dryer. As a consequence, one should 
be able to see these typical weather patterns in the dogs in the placebo 
groups. In the latter trial (IV,V) one could in fact see this as a trend in the 
placebo group dogs as they worsened or stayed the same during the cold 
winter months and got relief when the weather became warmer and dryer 
in spring. The owners in the first trial (III) filled out the first four weekly 
questionnaires during a period of constantly poor (subzero temperatures 
and unstable) weather in March/April, but according to the owners in both 
groups, their dogs’ greatest improvement in locomotion was at this time, 
during the first two weeks posttreatment, despite cold and damp weather. 
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Thus, the improvement seen at this time in both groups suggests that it 
could have been caused by the treatment.
Thirdly, measuring actual clinical response to treatments in studies for 
OA is difficult. The subjective and semi-objective assessments in studies 
can mask a large amount of errors, as patients do not behave in the 
same way at all times. When evaluated at a hospital by researchers, the 
dogs are in a strange environment, where they tend to be apprehensive, 
nervous, or excited, therefore masking signs of pain (Dobromylskyj et 
al. 2000). Memories from a previous visit can make dogs either happy or 
uncooperative, either exaggerating or masking the variables assessed (e.g. 
pain, willingness to jump, allowing hind limb extension) (Dobromylskyj 
et al. 2000).
Fourthly, even if a treatment is successful, there may still be loss of 
extension and abduction and the gait may be affected due to bony changes 
and changes of the cartilage (Edge-Hughes & Nicholson 2007). There may 
also be a certain degree of habit involved, e.g. an acquired abnormal gait 
will not disappear immediately even when the cause of the pain is removed 
(Edge-Hughes & Nicholson 2007). 
Fifthly, repeated visits to the hospital may reinforce general advice such 
as that on nutritional requirements, weight control, exercise modification 
etc. (Carmichael 2005). This may benefit dogs unequally; thus, emphasis 
should be placed on giving all owners the same information.
Last we have a problem that influence all research; placebo effect. 
In clinical trials of a chronic deliberating disease, a positive outcome is 
obviously desired. The desire for improvement tends to make evaluators 
answer more positively, and a positive placebo effect may be seen, especially 
in owners’ questionnaire responses. To counteract this bias and all other 
bias from factors that might affect dogs in the study, randomization and 
a negative control group that received the treatment as a sham treatment 
or the product as a placebo product, were used in all of our clinical trials 
(III-V). Although variation should not influence results between groups 
in a randomized placebo controlled clinical trial, it might still influence 
results despite groups. 
Positive controls are used when two reference points for clinical outcome 
evaluation are desired, and when testing for bioequivalence. When doing 
research on complementary treatments and remedies it is even more 
important to use two control groups, as positive results in these disciplines 
are not readily accepted. Both, showing that a treatment is better than a 
placebo and evaluating its clinical relevance, are warranted. In a chronic 
pain trial like ours, an established canine analgesic should be used as a 
reference (IV,V) (Holtsinger et al. 1992, Vasseur et al. 1995). The Helsinki 
Convention (WMA 1964) states that human placebo groups not should 
be used if one can use equivalence groups and these ethical principles are 
often referred to, also concerning animal studies. However, we still feel 
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that it is very important to use both placebo and positive control groups 
when we are dealing with treatments where positive results are not readily 
accepted by the profession. If they are left out, it will be near to impossible 
to do good, objective research on controversial treatments such as 
homeopathy. Therefore we recommend the use of placebo groups in both 
human and animal CAM research, providing that there is no risk of serious 
or irreversible harm. In a newer clarification of the Helsinki convention, 
paragraph 29, this is nowadays also stated (WMA 2002). 
Gold bead implants (iii)6.3.2 
In the first clinical trial (III) the hypothesis was that implanting small 
pieces of gold wire near the hip joint would alleviate signs of pain due to 
OA in dogs. However, a similar result was yielded for both the treatment 
and the control group; there was an improvement of some 53 to 65% in 
both groups. The percentage in the treatment group was slightly lower than 
expected compared to both previous and new studies. As the veterinary 
evaluation in our study was quite strict, (to be considered “improved”, 
none of the five parameters could be negative), this could possibly have led 
to a lower rate of improved. Recently two similar studies including placebo 
groups have been reported, one indicating success of the technique (Jaeger 
et al. 2006, 2007), the other failure (Bollinger et al. 2002).
Jaeger et al. (2006) found 83% of gold bead-implanted dogs to have a 
65% reduction of pain, whereas 60% of placebo dogs had a reduction of 
only 36% six months after the treatment. Comparing these results with 
ours, 60% of their control dogs also got “treated”. Jaeger et al. also used a 
placebo group where five big needles penetrated the skin at nonacupoints 
close to the hip. Bearing in mind the recent f-MRI studies where all kinds 
of needle penetrations, regardless of point location, led to analgesia (Cho 
et al. 2002a,b), it seems possible that both Jaeger et al.’s and our study 
suffered from the same type of placebo group flaw, where the placebo 
group unintentionally became a second treatment group. Acupuncture 
has long had a problem concerning placebo interventions. Researchers 
have therefore now suggested new types of sham acupuncture treatments, 
for example a needle that retracts into the shaft and does not penetrate 
the skin (Park et al. 2002, McManus et al. 2007). A “profile of quality of 
life in the chronically ill”-index gave significantly better results for the 
real acupuncture group than for the group that used this sham-device in 
conjunction with NSAID treatment, for humans with knee OA (Vas et al. 
2004). Other type of study designs, such as randomized pragmatic study 
designs or randomized cluster designs, have also been suggested (Paterson 
& Dieppe 2005). 
The size of the needle is also important. In both Jaeger et al.’s and our 
studies, the needle used for both groups was 14 G (∅ 1.2 mm). A normal 
acupuncture needle (∅ 0.25-0.38 mm) is supposed to give a subtle 
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treatment, whereas very thick needles, according to ancient Chinese texts 
are used only to get drastic results, as for paralyzed patients, etc. (Veith 
1973). As pain inhibition outside the painful area varies directly with the 
stimulus intensity (Helms 1995), the big needles possibly induced analgesia 
easier than had they been very thin. However, the same placebo effect has 
frequently been reported also in human studies, even with thin needles. 
Gaw et al. (1975) found that sham-acupuncture (by normally needling, at 
nonacupuncture placebo points) and real acupuncture both gave significant 
pain relief (P<0.05). Thomas et al. (1991) reported that sham-acupuncture 
(only very shallow intra-dermal needling) gave nearly as good pain relief 
(P<0.05) as real acupuncture (P<0.005), compared with diazepam (P<0.05) 
and placebo-diazepam (no significant pain relief). 
As we used only one piece of gold per point and only implanted three 
points, this might have lead to a smaller effect than other researchers have 
reported. Jaeger et al. (2006) used two gold wire pieces per site and implanted 
five points, thus, a total of 10 beads per hip. Danscher (2002) showed that 
the gold wire pieces at least partly induced their effect by losing gold ions 
that have an influence on pain via anti-inflammatory mechanisms. He 
also showed that the more gold implanted, the more ions could be found 
over a bigger area, possibly alleviating OA more. In a continuing study, 
Jaeger et al. (2007) found that the pain-relieving effect of the gold implants 
continued throughout a two-year follow-up period. Our follow-up study 
had similar results (Hielm-Björkman 2003).
Another controlled double-blinded study on gold implants for OA 
showed that the acupuncture group, according to force plate measurements, 
actually was statistically worse after a one-month follow-up, but there was 
no significant difference between groups (Bollinger et al. 2002). The lack 
of treatment success in their study was similar for all assessed treatment 
outcome variables; only 10-30% of dogs improved in treatment and control 
groups. These results contradict all other studies and anecdotal results to 
date. The small group size in Bollinger’s study may have weakened their 
results; in the present study we had 19/19, Jaeger et al. 36/42, and Bollinger 
et al. only 9/9 dogs in the treated/placebo groups, respectively.
In some earlier reports, the treatment seemed to work best in young 
dogs with minimal bony changes (Durkes 1994, Klitsgaard 1995). In our 
study, 40% of the dogs had a history of pain for more than two years. Many 
dogs (22%) had also previously been operated on without success. The age 
distribution of our patients was also very different from that of Klitsgaard 
(1995); we had 40% of dogs aged under four years in our gold implant 
study, while Klitsgaard had 70% of their dogs aged under four years. The 
age distribution was not reported in Jaeger et al. (2006) or in Bollinger et 
al. (2002). 
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GLm6.3.3 
Our results of the GLM study are in agreement with those of the newer 
human and animal trials. In the early GLM clinical trials on human 
patients suffering from OA, the outcomes were not very good and often 
contradictory (Gibson et al. 1980, Huskisson et al. 1981). However, 20 
years later, possibly after having stabilized the product by freeze-drying 
and lyophilizing (Broadbent & Kosuge 1985), the results of clinical trials 
for GLM have been much more promising (Gibson & Gibson 1998, Bierer 
& Bui 2002, Cho et al. 2003, Pollard et al. 2006, Lawson et al. 2007). The 
product tested here is a version of this newer stabilized powder product. 
Four studies have been published on stabilized GLM in the treatment 
of canine OA, and our findings are consistent with three of them. Bierer 
and Bui (2002) conducted three six-week, randomized, double-blind trials 
in which they compared three different GLM dog feeds with control feeds. 
As in our study, all individual variables in Bierer and Bui’s study did not 
show a significant improvement, although a significant change was seen 
in the total arthritis score in favor of the three GLM test groups. Of the 
eight variables evaluated, only two (joint pain and joint swelling) were 
significantly improved at week 6 in the GLM groups in all three trials, and 
joint crepitus improved significantly in two of the trials. GLM thus seems to 
have an effect first on the joint surface, whereas secondary positive effects 
such as mobility and ROM, are seen later. 
A multicenter field study - with no placebo groups - testing a GLM 
supplemented dry diet, showed statistically significant positive outcome 
results, that were similar to ours (Servet et al. 2006). At the end of the 50 
day trial, veterinarians evaluated 94% of dogs to have improved arthritic 
signs and evaluated 3 different negative scores to be reduced by 33-36% 
from baseline (Servet et al. 2006).
A third double-blind, placebo-controlled canine trial studied a slightly 
different product that ours, but also had results that complied with ours. 
They used a product containing GLM and brewer’s yeast, with the placebo 
made of brewer’s yeast and dried fin-fish (Pollard et al. 2006). However, the 
use of this placebo group renders the trial results unreliable in our opinion, 
as one would expect the placebo group to improve at least to some extent, 
as cartilage, bone, minerals and fatty acids from the dried fish (Anthony et 
al. 1983) all might stimulate cartilage and bone metabolism and as brewer’s 
yeast can stimulate both mobility and mental activity (Hielm-Björkman 
et al. 2007). This effect was also seen in the results, as the pain scores 
decreased in both groups. However, even with their poor study design, 
the improvement continued throughout the study period (112 days), 
showing a significant positive result for the GLM group from day 54. The 
slow onset of effect was also seen in our trial, where the effect continued 
to grow slowly through the whole study period, even after cessation of 
treatment, and could be seen e.g. as minimal use of extra carprofen at the 
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W12 follow-up. GLM has been shown to have a slower onset (Audeval & 
Bouchacourt 1986, Cleland et al. 1988, Kremer 1991, Volker & Garg 1996) 
and a longer effect (Gibson & Gibson 1980) than fast working NSAIDs. 
One of the first human studies indicated that the beneficial effects of GLM 
treatment could last for 2-3 weeks after cessation of therapy, if given at least 
for two months (Gibson &Gibson 1980). 
From all of the GLM results, we can conclude that the study period 
should be long enough to be able to detect secondary changes, like 
improvement in mobility. Human studies that tested similar fatty acid 
products were unable to show a significant improvement compared with 
controls before patients had ingested test products for at least 3-6 months, 
indicating the slow onset of the effect (Cleland et al. 1988, Kremer 1991, 
Volker & Garg 1996, Cobb & Ernst 2005). 
Apart from the fatty acids, the other main ingredient in GLM is 
chondritin sulphate (that is made up from glucosamine and galactosamine) 
so results from studies on these ingredients also interest us. A double-blind, 
controlled study testing a glucosamine/chondroitin sulphate combination 
for dogs suffering from OA also had a result that was in agreement with 
ours; it showed a significantly positive treatment response, but only at day 
70 (McCarthy 2007). Another glucosamine/chondroitin sulphate trial 
for OA dogs showed no effect, but here the treatment period was only 60 
days (Moreau et al. 2003). This indicates that also treatments targeting the 
cartilage matrix need a long time to show effect.
In the fourth GLM trial for dogs suffering from OA Dobenecker et al. 
(2002) used a smaller dose of GLM, only 25% of the dose used by Bierer 
and Bui (2002), Servet et al. (2006) and our initial dose. No improvement 
was found in dogs fed GLM compared with the placebo group, possibly 
indicating that our dose, as well as the doses of the other above presented 
studies, were more effective than that of Dobenecker’s group. 
Hcp6.3.4 
Our results showed that four of the six measured variables showed a 
significant difference in the HCP group compared with the placebo group 
in number of improved subjects per group or in improvement rate overall, 
and mostly in both. This was somewhat surprising but interesting. 
There is a growing body of research that supports homeopathic medicine, 
regarding both basic research on mechanisms of action and clinical trials 
(Bellavite 2006b). On a more general level, our results are in accordance 
with Linde et al. (1997), who in the Lancet had reviewed 89 randomized, 
placebo-controlled trials in a thorough meta-analysis. A statistically 
significant difference between the groups in favor of homeopathy was 
evident. The groups receiving homeopathic treatments had a combined 
odds ratio of 2.45 (95% CI 2.05, 2.93), the odds ratio for the 26 best-quality 
studies being 1.66 (1.33, 2.08), and, after correction for publication bias, 
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1.78 (1.03, 3.10). Of the trials included, 67% reported a positive outcome 
for their trial group. Two other meta-analyses published in the British 
Medical Journal and Lancet yielded similar results (Kleijnen et al. 1991, 
Shang et al. 2005). Other meta-analyses have found no positive effect of 
homeopathy (Ernst 2002, Altunc et al. 2007). A “bias of the observer” 
has been shown to exist when choosing trials for these meta-analyses, 
possibly partly explaining these different results (Frass et al. 2005, Kiene 
et al. 2006). However, in many meta-analyses it has been shown that more 
rigorous trials tend to yieald less optimistic results than trials with less 
precaution against bias (Linde et al. 1999, Shang et al. 2005), but there is 
no linear relationship between quality scores and study outcome (Linde et 
al. 1999).
Our results compare well with a trial published earlier this autumn 
where Zeel® ad us. vet. was compared to carprofen treatment in dogs with 
OA (Neumann et al. 2007). In this study Zeel® was statistically equivalent 
to the positive control carprofen at all evaluation times (days 28, 56 and 
70) and the effect persisted longer in the Zeel® group than in the carprofen 
group after discontinuation of the treatment. A big difference between the 
Neumann et al. study and ours was dose and mode of treating. We used 
a lower dosing than that used in the Neumann study, which is the one 
currently recommended. The recommentdation at the beginning of our 
study was giving only ½-1 ampoule once per day, which is 1/3 of the now 
recommended dose. We also used a drinkable ampoule, whereas the Zeel® 
ad us. vet. nowadays comes as a pill. Whether these modifications had an 
impact on the results is unknown but in conventional pharmacology one 
can suppose that a dose is increased if it has been shown to be too low but 
this might not be the case for homeopathical therapies. We have found no 
publication on this.
Our results are also comparable with some double-blinded research that 
has been done with HCP Zeel® in human and equine patients suffering from 
OA. A therapeutic equivalence was found between the NSAID Diclofenac 
and Zeel®; after six weeks, the treatment outcome of 47% of the human group 
receiving Zeel® and 51% of the group receiving Diclofenac was evaluated 
as good/very good (Maronna et al. 2000). In two other comparative trials 
Zeel® comp. was found to be as good as hyaluronic acid for human OA 
(Nahler et al. 1996) and Zeel® ad us vet. was found to be equivalent to 
hyaluronic acid for equine OA (Faulstich et al. 2006). Our results compare 
with a human trial with knee OA patients (n=592) where Zeel Comp. N 
at the six week check-up was found to be noninferior to treatment with 
two coxibs at an equivalence limit of 10% (one-sided probability of error = 
0.025)(Birnesser et al. 2003). However, none of these trials included placebo 
groups, referring to the equivalence study guidelines (WMA 1964). 
No adverse reactions were seen in our study, as is usually the case 
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with homeopathic remedies. However, in low-dilution remedies, some 
ingredient might cause a reaction if the patient is allergic to it, e.g. a 
reaction towards Zeel® may arise because of rhus toxicodendron (Poison 
Ivy), a poisonous plant. 
Another aspect of this particular study still has to be addressed. The fact 
that the product tested is a low-dilution homeopathic remedy and actually 
includes measurable amounts of ingredients does for many mean that the 
product is not a “true” homeopathic remedy. As described in the littereture 
review; all products that treat a disease symptom according to the similia 
principle and are diluted from a homeopathic mother tincture using the 
potentizing method, are homeopathic remedies. All are not voided from 
material other than water or sugar, however. The fact that Zeel® ad us vet. 
actually includes materia in measurable amounts could in fact explain 
our good results in a way that would satisfy both the homeopath and the 
sceptic. It might be possible that the summed amount of very small amounts 
of ingredients with anti-inflammatory properties could indeed result in 
a detectable anti-inflammartory effect. Birnesser & Stolt (2007) recently 
published a nice review looking at research on the individual constituents 
of Zeel®. Arnica Montana’s constituents helenaline and dihydrohelanine 
have been shown to possess anti-inflammatory properties (Mascolo et al. 
1987) and Solanum dulcamara was shown to highly inhibit platlet activating 
factor-exocytosis (Tuno´n et al. 1995). This aspect is also supported by the 
research where high-dilutions, 12c, 30c and 200c of Rhus Toxicodendron 
showed smaller and non-significant effects on induced rat and mice edema 
whereas a significant anti-inflammatory effect was present with a 6c dose 
(dos Santos et al. 2007). The amount of Rhus Toxicodendron substance in 
this 0.5 ml oral dose of 6c dilution was, however, very small. Valentiner et 
al. (2003) had also found that the inhibitory effect of cell proliferation of 
Rhus Toxicodendron at D1-D2 was significant, but the more diluted doses 
were not significantly effective anymore. In a meta-analysis LÜdtke and 
Hacke (2005) looked at homeopathical Arnica Montana studies and found 
a significant OR on effectiveness for the evaluated trials but also here, the 
better quality studies were less likely to report positive results. We can here 
only conclude that it would be interesting to know if the amount of materia 
in our tested product actually was the reason to our treatment success or if 
it would have worked also in higher dilutions, as a “classic” homeopathic 
remedy.
statistical methods6.3.5 
In the gold implant study (III), unpaired two-tailed parametric tests were 
used, according to the original study protocol. When setting up the second 
study, we planned to compare the groups with respect to their change in 
mean between W0-W8 for each treatment outcome variable. All of the data 
could not, however, be analyzed according to the original study protocol 
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so the data in the second trial (IV,V) was converted into dichotomous 
variables. This can be criticized, as it marginally may increase the chances 
of getting a more positive outcome in a study but we justify this conversion 
by having four of the 15 dogs in the placebo group using rescue analgesia, 
i.e. extra NSAIDs 3-5 times per week or more, at the end of treatment, at 
our most important point of treatment evaluation, W8. This probably led 
the placebo group evalvators to answer the questionnaire differently than if 
the dogs had not taken the extra carprofen. Also, lameness and force plate 
measurements were likely to be inaccurate, as nearly 30% of the group 
probably showed less lameness and used more ground reaction forces than 
if they had not taken extra analgesic medication. In fact, they were probably 
showing treatment effects that were closer to those of the carprofen group 
than to the no-treatment placebo group. The placebo group, thus, both 
did and did not receive effective analgesia, and we could neither use these 
results while calculating means, nor did we want to exclude them. That all 
four dogs taking extra analgesia came from the placebo group is already a 
result to be considered, and the only way all data could be included, was 
to convert the results into dichotomous responses. As this result did not 
express the degree of clinical improvement, this was tested for separately 
and again we wanted to use the whole data. The change of values for the 
dogs using the rescue analgesia was justified with the assumption that 
although some other owner’s dog also was in similar pain, this other owner 
had decided that their dog would be ok without the rescue carprofen. As 
we gave the same value to four of the placebo dogs and thereby not had 
a normal distribution at W8, we had to use a nonparametric test when 
evaluating range of improvement. Although significance is harder to show 
with nonparametric tests (Greenhalgh 1997), we had significant differences 
with both GLM and HCP treatments compared with placebo.
working mechanisms of treatments used in this study6.3.6 
Basic research provides possible mechanisms of action for all three of the 
treatments used, therefore indicating that our positive treatment results 
may be true. As the most attractive new strategies for really “treating” 
OA have been to target (1) the inflammatory process (by cytokines such 
as IL-1β, NO, reactive oxygen species and eicosanoids), (2) the cartilage 
degradation (by MMP-13 and Aggrecanase-2), (3) the subcondral bone 
remodelling (by biophosphonates) (Pelletier et al. 2006) and (4) by 
controlling gene expression (Gelse et al. 2005), we seem to have several of 
these as mechanisms of action in our tested treatments. 
GLM and acupuncture significantly reduce pro-inflammatory cytokines 
IL-1, IL-6, IL-12p40, TNF-α, and anti-collagen IgM antibodies, IgG levels 
(Mani & Lawson 2006, Yim et al. 2007, Lawson et al. 2007). IFN-γ can 
decrease after acupuncture stimulation (Yim et al. 2007). Acupuncture 
has been shown to increase T-, B-, and NK-cell activity (Yamaguchi et al. 
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2007). GLM may also mediate T-helper cell regulation (Mani & Lawson 
2006), and has been shown to ameliorate CIA in mice by decreasing INF-α 
and other catabolic pro-infammatory cytokines (Lawson et al. 2007). 
Ingredients in the HCP product may inhibit fibroblasts and leukocyte 
elastase activity (Stancikova 1999b, Valentiner et al. 2003). Research also 
suggests anti-inflammatory and immuno-regulatory effects similar to those 
in dual inhibitor NSAIDs; both GLM and the HCP have been established 
to inhibit prostaglandin synthesis by COX-1 and COX-2 enzymes and 
leukotriene production by 5-LOX (Whitehouse et al. 1997, Jäggi et al. 2004, 
Mani & Lawson 2006).
All the above mentioned mechanisms plus many more reviewed in the 
literature review before, would indicate that the researched treatments 
indeed could be beneficial in the treatment of OA. 
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CONCLUSIONS7. 
Trials aimed at finding and testing suitable treatment outcome measures 
and measures of chronic pain to be used for assessment of chronic 
pain in clinical trials of treatments for canine OA led to the following 
conclusions: 
1. There are many different ways to evaluate canine chronic pain in 
research, but only a few of them have proven to be both valid and reliable. 
Examination using radiographs, plasma stress hormones, or force plates 
could not with certainty identify dogs suffering from chronic OA pain. 
The pain and locomotion VASs should be evaluated further. The MDS 
questionnaire proved to be the most appropriate of the methods tested. 
The 11 most relevant questions, which were also easy to answer for all 
kinds of owners, with all types of dogs and living in all types of home 
environments, were combined to form the Helsinki chronic pain index 
(HCPI).
2. The Helsinki chronic pain index – HCPI - was evaluated and found 
to be a simple, reliable and valid canine pain questionnaire. It was 
validated against sound dogs and was repeatable under identical 
conditions (reliability), sensitive to changes in pain (responsiveness), 
and, according to the principal component analysis, had a stable single 
component structure. We propose that the index be used as an outcome 
measure in both research and clinical work to evaluate chronic OA pain, 
by owners.
Trials testing three different treatments for canine OA using randomized, 
controlled double-blind study design led to the following conclusions: 
3. In the first trial, gold wire pieces implanted around the coxofemoral 
joint in dogs with OA due to CHD did not show a significant difference 
in reducing pain between the treatment and sham group. As 53-65% 
of both groups improved, the placebo group may have not been a real 
“no treatment” group, instead possibly behaving like an acupuncture 
group. Also, big variability or changes in the disease pattern of OA 
may have influenced the results. More research is indicated before any 
recommendations can be given.                                  
 The second trial tested a green lipped mussel product and a low-dose 
homeopathic combination preparation in the treatment of OA pain. 
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Both products improved significantly more dogs in the treatment groups 
than in the placebo groups, and overall improvement was significantly 
better in both treatment groups compared with the placebo group, 
although they were not as effective as our positive control, carprofen. As 
no side-effects were seen, both green lipped mussel and the combination 
preparation Zeel® ad us vet. may be beneficial for use in treating canine 
OA, especially for dogs that either cannot tolerate NSAIDs due to their 
side-effects or that require long-term management.
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EPILOGUE8. 
When conducting research on complementary treatments, rigorous 
trial design is of the utmost importance. Many New Age healers or 
complementary medicine practitioners - while roundly denouncing 
medicine - seek medicine’s cover to make their own miraculous claims 
respectable. As the domain of medicine is defined by certain goals, 
principles, measure of outcomes, and standards of evidence (Schneiderman 
2000), “complementary” medicine should be defined similarly, to get the 
same status. This new positive attitude toward research can already be seen 
in CAM studies of today; study quality is rising rappidly.
When using animals as patients, the placebo response to the treatment 
is considered to be lower than when using humans. Animals have been 
used in pre-clinical drug testing for decades and are especially valuable 
in research of diseases that have a similar pathology in animals and in 
humans. The dog, suffering from a very similar OA to man, is an excellent 
species to use while testing new treatments for this disease. Dogs have been 
used extensively in this research, particularly as the Pond–Nuki model of 
OA (Pond & Nuki 1973). At the same time, we as veterinarians can benefit 
from their trial results and use the obtained knowledge for the benefit of 
our patients. 
Our results may indicate that sham-acupuncture and gold bead 
implants, as well as carprofen, GLM, and HCP, have significantly positive 
effects on pain and lameness, due to canine OA. But, as evidence-based 
medicine requires a multitude of well-conducted high quality trials to be 
able to evaluate each of these treatments in large meta-analyses, and as 
our findings come from small studies and are among the first published 
RCTs on these treatments for this condition, we are, at this time, unable to 
give any evidence based recommendations about their benefits. But, as the 
fruits from this labor will not be at our disposal for another decade or so, 
at least there are now more and more of us that work in this controversial 
field. With time, a RCT derived critical mass point will tip these therapies 
over; some this way, some that way.
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APPENDIX
appendix 1. psychometric properties of a scale
For a scale to be of use, it has to be both valid and reliable and this is 
evaluated by its psychometric properties (Cronbach 1951, Siegel 1956, 
Nunnally 1978, Carmines & Zeller 1979, Cohen 1988, Kline 1993, Streiner 
& Norman 1995, Johnston 1998, DeVellis 2003, Tabachnick & Fidell 
2007).
VALIDITY is the quality of a scale, its ability to measure what it is 
supposed to measure. Validity can be divided into four different types: 
face validity and content validity rely on the internal logic of the measure; 
criterion validity and construct validity are less subjective and more 
empirical. 
Face validity is the extent to which the scale or index is subjectively 
viewed by knowledgeable individuals as covering the con cept, e.g. that 
each variable in the questionnaire measures chronic pain in some way. 
Content validity is related to face validity, being based on logic and 
expertise. It asks whether the scale or index covers all of the generally 
accepted variables of for example, chronic pain, i.e. is it sufficiently 
comprehensive? 
Criterion validity is used when describing the correlation between a 
scale and another, already validated external measurement, of the same 
phenomenon. 
Construct validity has to do with the ability of the scale or index to 
measure variables that are theoretically related to the variable that the scale 
purports to measure.
RELIABILITY refers to the extent to which the measure yields the same 
score each time it is administered, all other things being equal. There are four 
types of reliability: Repeatability, inter-rater reliability, internal consistency 
reliability, and responsiveness. Thus, reliability can be measured in different 
ways and is always inexact but more tests done, strengthen the index.
Internal consistency or equivalence is when the reliability of the 
instrument is judged by estimating how well the items that reflect the 
same construct yield similar results or how consistent the results are for 
the different items for the same construct within the measure and the 
Cronbach’s coefficient α (Cronbach 1951) is the best known method for 
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evaluating this. The cause for unreliability may lie in one or more questions 
being vague or confusingly worded. As a result, the reader’s interpreta tion 
at the second reading may have differed from the initial interpretation of 
the same variable. 
Repeatability (also called stability, test-retest, temporal reliability 
and intra-observer reliability) is when a test is given twice to the same 
people and thereby evaluated by the test-retest method. When the measure 
is taken over intervals of time, the scores of the owners should remain 
consistent. This is often tested using intra-class correlation (Streiner & 
Norman 1995) but also many other tests are possible, e.g. Cohen’s Kappa 
(Cohen 1988), Spearman- (Siegel 1956) or Pearson- (Streiner & Norman 
1995) correlation tests. 
Inter-rater reliability (also called Inter-observer reliability) is when 
two observers rate the same phenomenon at the same time, e.g. two 
veterinarians evaluating the same dog at the same time using the same 
scale. 
Responsiveness (also called sensitivity to change) of the scale reflects 
the capability of the instrument to measure changes in levels of pain 
over time, in particular, in responses to clinical interventions such as 
analgesics.
Cut-off points on pain scales are points on the scale that differentiate 
between mild, moderate, and severe pain, between pain being tolerable 
and intolerable, thus indicating where (additional) analgesics are needed 
because the dog is experiencing too much pain. Cut-off points must be 
reliable and valid for each population.
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appendix 2: 
 1
HELSINKI CHRONIC PAIN INDEX
 
Name of Dog ________________          Owner _______________________________          Diagnosis________________________
Date _________       Questionnaire no.__________
Tick only one answer – the one that best describes your dog during the preceding week  
      Points  
1. Rate your dog’s mood:
 Very alert alert neither alert,     indifferent very indifferent 
   nor indifferent  
? ? ? ? ? _____ 
   
2. Rate your dog’s willingness to participate in play: 
 Very willingly    willingly reluctantly             very reluctantly       does not at all 
? ? ? ? ? _____ 
3. Rate your dog’s vocalization (audible complaining, such as whining or crying out): 
 Never hardly ever sometimes often very often 
? ? ? ? ? _____ 
4. Rate your dog’s willingness to walk: 
 Very willingly    willingly reluctantly             very reluctantly    does not walk at all 
? ? ? ? ? _____ 
5. Rate your dog’s willingness to trot: 
 Very willingly    willingly reluctantly             very reluctantly    does not trot at all 
? ? ? ? ? _____ 
6 Rate your dog’s willingness to gallop: 
 Very willingly    willingly                  reluctantly       very reluctantly        does not gallop at all 
? ? ? ? ? _____ 
7 Rate your dog’s willingness to jump (eg. into car, onto sofa…) 
 Very willingly    willingly                  reluctantly            very reluctantly        does not jump at all 
? ? ? ? ? _____ 
8. Rate your dog’s ease in lying down: 
 With great      easily  neither easily,         with difficulty              with great                 
        ease    nor difficultly                      difficulty 
? ? ? ? ? _____ 
9. Rate your dog’s ease in rising from a lying position:  
 With great      easily  neither easily,         with difficulty              with great   
        ease    nor difficultly                      difficulty 
? ? ? ? ? _____ 
10. Rate your dog’s ease of movement after a long rest: 
 Never hardly ever sometimes often very often/always 
 difficult difficult difficult  difficult difficult 
? ? ? ? ? _____ 
11. Rate your dog’s ease of movement after major activity or heavy exercise: 
 Never hardly ever sometimes often very often/always 
 difficult difficult difficult  difficult difficult 
? ? ? ? ? _____ 
  _______________________________________________________________________
Points 0 1 2 3 4           
         
Total up the answers to all 11 questions.  Total chronic pain index score:          _____ 
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